HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	B-DNA
E	I-DNA
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	B-protein
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	B-protein
class	I-protein
I	I-protein
Ags	I-protein
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	B-protein
class	I-protein
I	I-protein
molecules	I-protein
can	O
induce	O
the	O
proliferation	O
of	O
aortic	B-cell_type
endothelial	I-cell_type
as	O
well	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	B-protein
protein	I-protein
in	O
the	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
as	O
well	O
as	O
human	B-cell_type
aortic	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
inactivation	O
of	O
Rb	B-protein
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	B-protein
Abs	I-protein
to	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	B-protein
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	B-protein
receptors	I-protein
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	B-protein
class	I-protein
I	I-protein
molecules	I-protein
induced	O
cyclin	B-DNA
E	I-DNA
-associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	B-protein
.	O

A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant-negative	B-DNA
cdk2	I-DNA
construct	I-DNA
prevented	O
HLA	B-protein
class	I-protein
I	I-protein
-mediated	O
inactivation	O
of	O
Rb	B-protein
;	O
in	O
contrast	O
,	O
dominant-negative	B-DNA
cdk4	I-DNA
and	I-DNA
cdk6	I-DNA
constructs	I-DNA
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	B-protein
D-associated	I-protein
kinase	I-protein
activity	O
upon	O
HLA	B-protein
class	I-protein
I	I-protein
ligation	O
,	O
suggesting	O
that	O
cyclin	B-protein
E-dependent	I-protein
kinase	I-protein
activity	O
mediates	O
Rb	B-protein
inactivation	O
,	O
leading	O
to	O
E2F	B-protein
activation	O
and	O
cell	O
proliferation	O
.	O

C	NULL
%	NULL
Flexible	NULL
,	NULL
Intuitive	NULL
,	NULL
and	NULL
Luminex	NULL
.	NULL

C	NULL
-	NULL
-ﬂ	NULL
‘	NULL
3	NULL
Affordable	NULL
Cytometry	NULL
.	NULL

wwarnmore	NULL
:	NULL
complexity	NULL
simplified	NULL
.	NULL

Guava®	NULL
easyCyte	NULL
``	NULL
Flow	NULL
Cytometers	NULL
.	NULL

is	NULL
meJournal	NULL
o	NULL
HLA	NULL
Class	NULL
I-Mediated	NULL
Induction	NULL
of	NULL
Cell	NULL
'	NULL
Immunolo	NULL
gy	NULL
Proliferation	NULL
Involves	NULL
Cyclin	NULL
E-Mediated	NULL
Inactivation	NULL
of	NULL
Rb	NULL
Function	NULL
and	NULL
Induction	NULL
of	NULL
E2F	NULL
Activity	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Niharika	NULL
Nath	NULL
,	NULL
Hong	NULL
Bian	NULL
,	NULL
Elaine	NULL
F.	NULL
Reed	NULL
and	NULL
Srikumar	NULL
P.	NULL
Chellappan	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:5351-5358	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/9/5351	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
63	NULL
articles	NULL
,	NULL
22	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/9/5351	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
HLA	NULL
Class	NULL
I-Mediated	NULL
Induction	NULL
of	NULL
Cell	NULL
Proliferation	NULL
Involves	NULL
Cyclin	NULL
E-Mediated	NULL
Inactivation	NULL
of	NULL
Rb	NULL
Function	NULL
and	NULL
Induction	NULL
of	NULL
E2F	NULL
Activity	NULL
'	NULL
Niharika	NULL
Nath	NULL
,	NULL
Hong	NULL
Bian	NULL
,	NULL
Elaine	NULL
F.	NULL
Reed	NULL
,	NULL
``	NULL
and	NULL
Srikumar	NULL
P.	NULL
Chellappan	NULL
``	NULL
``	NULL
Chronic	NULL
rejection	NULL
of	NULL
transplanted	NULL
organs	NULL
is	NULL
manifested	NULL
as	NULL
atherosclerosis	NULL
of	NULL
the	NULL
blood	NULL
vessels	NULL
of	NULL
the	NULL
allograft	NULL
.	NULL

HLA	NULL
class	NULL
I	NULL
Ags	NULL
have	NULL
been	NULL
implicated	NULL
to	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
this	NULL
process	NULL
,	NULL
since	NULL
signaling	NULL
via	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
can	NULL
induce	NULL
the	NULL
proliferation	NULL
of	NULL
aortic	NULL
endothelial	NULL
as	NULL
well	NULL
as	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
show	NULL
that	NULL
HLA	NULL
class	NULL
I-mediated	NULL
induction	NULL
of	NULL
cell	NULL
proliferation	NULL
correlates	NULL
with	NULL
inactivation	NULL
of	NULL
the	NULL
Rb	NULL
protein	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
line	NULL
Jurkat	NULL
as	NULL
well	NULL
as	NULL
human	NULL
aortic	NULL
endothelial	NULL
cells	NULL
.	NULL

HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
can	NULL
be	NULL
inhibited	NULL
specifically	NULL
by	NULL
neutralizing	NULL
Abs	NULL
to	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
(	NULL
bFGF	NULL
)	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
FGF	NULL
receptors	NULL
in	NULL
the	NULL
signaling	NULL
process	NULL
.	NULL

Signaling	NULL
through	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
induced	NULL
cyclin	NULL
E-associated	NULL
kinase	NULL
activity	NULL
within	NULL
4	NULL
h	NULL
in	NULL
quiescent	NULL
endothelial	NULL
cells	NULL
,	NULL
and	NULL
appeared	NULL
to	NULL
mediate	NULL
the	NULL
inactivation	NULL
of	NULL
Rb	NULL
.	NULL

A	NULL
cdk2	NULL
inhibitor	NULL
,	NULL
Olomoucine	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
dominant-negative	NULL
cdk2	NULL
construct	NULL
prevented	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
dominant-negative	NULL
cdk4	NULL
and	NULL
cdk6	NULL
constructs	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

Furthermore	NULL
,	NULL
there	NULL
was	NULL
no	NULL
increase	NULL
in	NULL
cyclin	NULL
D-associated	NULL
kinase	NULL
activity	NULL
upon	NULL
HLA	NULL
class	NULL
I	NULL
ligation	NULL
,	NULL
suggesting	NULL
that	NULL
cyclin	NULL
E-dependent	NULL
kinase	NULL
activity	NULL
mediates	NULL
Rb	NULL
inactivation	NULL
,	NULL
leading	NULL
to	NULL
E2F	NULL
activation	NULL
and	NULL
cell	NULL
proliferation	NULL
.	NULL

-	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
;	NULL
5351-5358.	NULL
he	NULL
cell	NULL
cycle	NULL
regulatory	NULL
machinery	NULL
can	NULL
respond	NULL
to	NULL
a	NULL
wide	NULL
array	NULL
of	NULL
extracellular	NULL
signals	NULL
and	NULL
modulate	NULL
the	NULL
prolifera-	NULL
tive	NULL
state	NULL
of	NULL
cells	NULL
accurately	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
machinery	NULL
to	NULL
respond	NULL
differentially	NULL
to	NULL
various	NULL
extracellular	NULL
signals	NULL
enables	NULL
cells	NULL
to	NULL
undergo	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
apoptosis	NULL
,	NULL
or	NULL
remain	NULL
in	NULL
a	NULL
quiescent	NULL
state	NULL
,	NULL
as	NULL
appropriate	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

An	NULL
understanding	NULL
of	NULL
how	NULL
extracellular	NULL
signals	NULL
received	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
contact	NULL
the	NULL
cell	NULL
cycle	NULL
machinery	NULL
would	NULL
enable	NULL
us	NULL
to	NULL
modulate	NULL
such	NULL
processes	NULL
for	NULL
therapeutic	NULL
purposes	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
multiple	NULL
signal	NULL
transduction	NULL
cascades	NULL
can	NULL
target	NULL
the	NULL
Rb	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
the	NULL
major	NULL
negative	NULL
regulator	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
had	NULL
indicated	NULL
that	NULL
growth-factor	NULL
stimulation	NULL
of	NULL
quiescent	NULL
cells	NULL
leads	NULL
to	NULL
the	NULL
inactivation	NULL
of	NULL
Rb	NULL
through	NULL
the	NULL
mediation	NULL
of	NULL
cyclin-dependent	NULL
kinases	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
was	NULL
further	NULL
extended	NULL
to	NULL
other	NULL
signaling	NULL
pathways	NULL
initiating	NULL
from	NULL
other	NULL
types	NULL
of	NULL
receptors	NULL
,	NULL
and	NULL
such	NULL
signals	NULL
were	NULL
also	NULL
observed	NULL
to	NULL
converge	NULL
on	NULL
Rb	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
normal	NULL
function	NULL
of	NULL
the	NULL
Rb	NULL
protein	NULL
is	NULL
regulated	NULL
by	NULL
kinases	NULL
associated	NULL
with	NULL
cyclins	NULL
D	NULL
and	NULL
E	NULL
,	NULL
and	NULL
phosphorylation	NULL
of	NULL
Rb	NULL
by	NULL
such	NULL
kinases	NULL
in	NULL
mid-to-late	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
leads	NULL
to	NULL
its	NULL
inactivation	NULL
(	NULL
12-15	NULL
)	NULL
.	NULL

The	NULL
interaction	NULL
between	NULL
Rb	NULL
and	NULL
its	NULL
major	NULL
downstream	NULL
target	NULL
,	NULL
the	NULL
E2F	NULL
transcription	NULL
factor	NULL
(	NULL
16-18	NULL
)	NULL
,	NULL
is	NULL
disrupted	NULL
upon	NULL
the	NULL
inactivation	NULL
of	NULL
Rb	NULL
,	NULL
and	NULL
this	NULL
facilitates	NULL
the	NULL
entry	NULL
of	NULL
cells	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
College	NULL
of	NULL
Physicians	NULL
and	NULL
Surgeons	NULL
,	NULL
Columbia	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10032	NULL
Received	NULL
for	NULL
publication	NULL
November	NULL
9	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
February	NULL
9	NULL
,	NULL
1999	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
American	NULL
Heart	NULL
Association	NULL
(	NULL
Charles	NULL
H.	NULL
Leach	NULL
II	NULL
Foundation	NULL
Grant-in-Aid	NULL
)	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
ROIAT	NULL
HL42819	NULL
to	NULL
E.F.R	NULL
.	NULL
)	NULL

,	NULL
and	NULL
Grant	NULL
RO-1CA63136	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
(	NULL
to	NULL
S.P.C	NULL
.	NULL
)	NULL

.	NULL

S.P.C	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
the	NULL
Irma-Hirschl	NULL
Trust	NULL
Research	NULL
Award	NULL
.	NULL

2	NULL
EF.R	NULL
.	NULL

and	NULL
S.P.C	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
project	NULL
.	NULL

3	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Srikumar	NULL
P.	NULL
Chellappan	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
College	NULL
of	NULL
Physicians	NULL
and	NULL
Surgeons	NULL
,	NULL
Columbia	NULL
University	NULL
,	NULL
630	NULL
W.	NULL
168th	NULL
St.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10032	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
spcl0	NULL
@	NULL
columbia.edu	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Rb	NULL
and	NULL
its	NULL
downstream	NULL
target	NULL
E2F	NULL
transcription	NULL
factor	NULL
have	NULL
been	NULL
found	NULL
to	NULL
respond	NULL
to	NULL
various	NULL
signaling	NULL
events	NULL
facilitating	NULL
proliferation	NULL
,	NULL
apoptosis	NULL
,	NULL
or	NULL
differentiation	NULL
,	NULL
and	NULL
are	NULL
believed	NULL
to	NULL
regulate	NULL
the	NULL
genes	NULL
expressed	NULL
during	NULL
such	NULL
processes	NULL
(	NULL
19-22	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
Rb	NULL
and	NULL
E2F	NULL
function	NULL
can	NULL
be	NULL
modulated	NULL
by	NULL
extracellular	NULL
signals	NULL
independent	NULL
of	NULL
the	NULL
cyclin/ecdk	NULL
pathway	NULL
(	NULL
23-25	NULL
)	NULL
;	NULL
for	NULL
example	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
the	NULL
signaling	NULL
kinase	NULL
Raf-1	NULL
physically	NULL
interacts	NULL
with	NULL
Rb	NULL
and	NULL
regulates	NULL
its	NULL
function	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
Raf-1/Rb	NULL
interaction	NULL
occurs	NULL
in	NULL
response	NULL
to	NULL
mitogenic	NULL
stimuli	NULL
and	NULL
leads	NULL
to	NULL
an	NULL
inactivation	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

Signals	NULL
that	NULL
are	NULL
not	NULL
proliferative	NULL
have	NULL
also	NULL
been	NULL
found	NULL
to	NULL
inactivate	NULL
Rb	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
;	NULL
furthermore	NULL
,	NULL
we	NULL
find	NULL
that	NULL
stimulation	NULL
of	NULL
the	NULL
Fas	NULL
receptor	NULL
in	NULL
Jurkat	NULL
cells	NULL
leads	NULL
to	NULL
an	NULL
inactivation	NULL
of	NULL
Rb	NULL
within	NULL
30	NULL
min	NULL
,	NULL
and	NULL
this	NULL
occurs	NULL
independent	NULL
of	NULL
cyclins	NULL
and	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

Fas-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
occurs	NULL
through	NULL
the	NULL
mediation	NULL
of	NULL
the	NULL
p38	NULL
kinase	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
family	NULL
.	NULL

p38	NULL
kinase	NULL
can	NULL
directly	NULL
phosphorylate	NULL
Rb	NULL
and	NULL
can	NULL
inactivate	NULL
Rb	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dominant-negative	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
nonproliferative	NULL
signals	NULL
like	NULL
cytokines	NULL
can	NULL
inactivate	NULL
E2F1	NULL
through	NULL
the	NULL
mediation	NULL
of	NULL
JNK1/SAP1	NULL
(	NULL
c-Jun	NULL
N-terminal	NULL
ki-nase/stress-activated	NULL
protein-1	NULL
)	NULL
kinase	NULL
(	NULL
69	NULL
)	NULL
.	NULL

Since	NULL
Rb	NULL
and	NULL
E2F	NULL
are	NULL
vital	NULL
regulators	NULL
of	NULL
cell	NULL
proliferation	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
,	NULL
we	NULL
attempted	NULL
to	NULL
evaluate	NULL
whether	NULL
they	NULL
mediate	NULL
proliferation	NULL
induced	NULL
by	NULL
specific	NULL
signals	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Attention	NULL
was	NULL
focused	NULL
on	NULL
HLA	NULL
class	NULL
I-mediated	NULL
signaling	NULL
,	NULL
which	NULL
has	NULL
been	NULL
demonstrated	NULL
recently	NULL
to	NULL
induce	NULL
proliferation	NULL
of	NULL
human	NULL
endothelial	NULL
cells	NULL
(	NULL
EC	NULL
)	NULL
*	NULL
and	NULL
smooth	NULL
muscle	NULL
cells	NULL
(	NULL
SMC	NULL
)	NULL
(	NULL
31-33	NULL
)	NULL
.	NULL

This	NULL
signaling	NULL
cascade	NULL
may	NULL
be	NULL
of	NULL
particular	NULL
importance	NULL
in	NULL
the	NULL
process	NULL
of	NULL
chronic	NULL
rejection	NULL
that	NULL
is	NULL
caused	NULL
by	NULL
the	NULL
proliferation	NULL
of	NULL
EC	NULL
and	NULL
SMC	NULL
of	NULL
the	NULL
vasculature	NULL
,	NULL
leading	NULL
to	NULL
obstruction	NULL
of	NULL
the	NULL
vessels	NULL
of	NULL
the	NULL
allograft	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Earlier	NULL
work	NULL
demonstrated	NULL
that	NULL
cross-linking	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
leads	NULL
to	NULL
an	NULL
induction	NULL
of	NULL
FGF	NULL
receptors	NULL
as	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
EC	NULL
,	NULL
endothelial	NULL
cell	NULL
;	NULL
FGF	NULL
,	NULL
fibroblast	NULL
growth	NULL
factor	NULL
;	NULL
bFGF	NULL
,	NULL
basic	NULL
FGF	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
EGM	NULL
,	NULL
endothelial	NULL
cell	NULL
growth	NULL
medium	NULL
;	NULL
PDGF	NULL
,	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
;	NULL
SMC	NULL
,	NULL
smooth	NULL
muscle	NULL
cell	NULL
;	NULL
TPA	NULL
,	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
.	NULL

0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
5352	NULL
well	NULL
as	NULL
the	NULL
appearance	NULL
of	NULL
multiple	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
in	NULL
EC	NULL
and	NULL
SMC	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Although	NULL
signaling	NULL
through	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
proliferation	NULL
or	NULL
apoptosis	NULL
in	NULL
activated	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
mediating	NULL
such	NULL
events	NULL
have	NULL
not	NULL
been	NULL
elucidated	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
attempt	NULL
to	NULL
determine	NULL
whether	NULL
signaling	NULL
through	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
affects	NULL
the	NULL
function	NULL
of	NULL
the	NULL
Rb	NULL
protein	NULL
,	NULL
and	NULL
characterize	NULL
the	NULL
specific	NULL
mechanisms	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
.	NULL

Attempts	NULL
were	NULL
also	NULL
made	NULL
to	NULL
evaluate	NULL
whether	NULL
modulation	NULL
of	NULL
Rb	NULL
through	NULL
the	NULL
Fas	NULL
receptor	NULL
and	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
occurs	NULL
through	NULL
different	NULL
mechanisms	NULL
.	NULL

We	NULL
find	NULL
that	NULL
ligation	NULL
of	NULL
class	NULL
I	NULL
molecules	NULL
with	NULL
anti-HLA	NULL
Abs	NULL
inactivates	NULL
Rb	NULL
through	NULL
the	NULL
specific	NULL
involvement	NULL
of	NULL
cyclin	NULL
E-dependent	NULL
kinases	NULL
,	NULL
whereas	NULL
Fas	NULL
achieves	NULL
Rb	NULL
inactivation	NULL
through	NULL
the	NULL
p38	NULL
kinase	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
find	NULL
that	NULL
cyclin	NULL
D	NULL
and	NULL
associated	NULL
kinases	NULL
are	NULL
not	NULL
involved	NULL
in	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
and	NULL
the	NULL
resulting	NULL
cell	NULL
proliferation	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
culture	NULL
and	NULL
transfections	NULL
Normal	NULL
human	NULL
aortic	NULL
EC	NULL
(	NULL
lot	NULL
2709	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Clonetics	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
maintained	NULL
in	NULL
EC	NULL
growth	NULL
medium	NULL
(	NULL
EGM	NULL
)	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
and	NULL
transfected	NULL
by	NULL
calcium	NULL
phosphate	NULL
precipitation	NULL
method	NULL
.	NULL

Jurkat	NULL
cells	NULL
grown	NULL
in	NULL
RPMI	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
were	NULL
electropo-rated	NULL
using	NULL
a	NULL
Bio-Rad	NULL
(	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
Gene	NULL
Pulser	NULL
;	NULL
cells	NULL
were	NULL
harvested	NULL
72	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
assays	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
and	NULL
B-galactosidase	NULL
were	NULL
performed	NULL
using	NULL
standard	NULL
protocols	NULL
.	NULL

A	NULL
pSV-Bgal	NULL
vector	NULL
was	NULL
included	NULL
in	NULL
all	NULL
transient	NULL
transfections	NULL
as	NULL
internal	NULL
control	NULL
.	NULL

Constructs	NULL
pDCE2F1	NULL
,	NULL
pE2CAT	NULL
,	NULL
and	NULL
pSVRb	NULL
(	NULL
68	NULL
)	NULL
as	NULL
well	NULL
as	NULL
dominant-negative	NULL
cdk2	NULL
,	NULL
cdk4	NULL
,	NULL
and	NULL
cdk6	NULL
have	NULL
been	NULL
described	NULL
before	NULL
.	NULL

A	NULL
total	NULL
of	NULL
2	NULL
ug	NULL
each	NULL
of	NULL
E2-CAT	NULL
,	NULL
pDCE2F1	NULL
,	NULL
and	NULL
pSVRb	NULL
was	NULL
used	NULL
in	NULL
all	NULL
transfections	NULL
.	NULL

HLA	NULL
class	NULL
I	NULL
,	NULL
bFGF	NULL
,	NULL
and	NULL
Fas	NULL
stimulation	NULL
Jurkat	NULL
cells	NULL
grown	NULL
in	NULL
RPMI	NULL
containing	NULL
10	NULL
%	NULL
FBS	NULL
were	NULL
stimulated	NULL
with	NULL
50	NULL
ng/ml	NULL
of	NULL
an	NULL
anti-Fas	NULL
Ab	NULL
(	NULL
MBL	NULL
Laboratories	NULL
,	NULL
Watertown	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
2	NULL
h	NULL
before	NULL
harvest	NULL
.	NULL

A	NULL
total	NULL
of	NULL
200	NULL
M	NULL
of	NULL
Olomoucine	NULL
or	NULL
10	NULL
M	NULL
of	NULL
$	NULL
B203580	NULL
was	NULL
included	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
during	NULL
stimulation	NULL
when	NULL
appropriate	NULL
.	NULL

Stimulation	NULL
with	NULL
10	NULL
ng/ml	NULL
of	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
and	NULL
10	NULL
ug/ml	NULL
of	NULL
W6/32	NULL
,	NULL
an	NULL
IgG2b	NULL
murine	NULL
mAb	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
monomor-phic	NULL
epitope	NULL
on	NULL
HLA	NULL
class	NULL
I	NULL
Ags	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
,	NULL
was	NULL
conducted	NULL
for	NULL
6	NULL
h	NULL
before	NULL
harvest	NULL
.	NULL

Similarly	NULL
,	NULL
aortic	NULL
EC	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
0.6	NULL
ng/ml	NULL
of	NULL
bFGF	NULL
for	NULL
6	NULL
h.	NULL
Neutralizing	NULL
Abs	NULL
to	NULL
bFGF	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
,	NULL
PDGF	NULL
,	NULL
TGF-§	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
murine	NULL
IgG	NULL
(	NULL
10	NULL
pg/ml	NULL
each	NULL
)	NULL
were	NULL
included	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
during	NULL
the	NULL
period	NULL
of	NULL
stimulation	NULL
,	NULL
where	NULL
appropriate	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
kinase	NULL
assays	NULL
Abs	NULL
to	NULL
cyclins	NULL
D	NULL
and	NULL
E	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnologies	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

For	NULL
immunoprecipitations	NULL
,	NULL
200	NULL
ug	NULL
of	NULL
cell	NULL
lysates	NULL
prepared	NULL
in	NULL
M2	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
3	NULL
mM	NULL
EDTA	NULL
,	NULL
3	NULL
mM	NULL
EGTA	NULL
,	NULL
and	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
was	NULL
treated	NULL
with	NULL
5	NULL
pl	NULL
of	NULL
the	NULL
appropriate	NULL
primary	NULL
Ab	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
100	NULL
pl	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h.	NULL
A	NULL
total	NULL
of	NULL
3	NULL
mg	NULL
of	NULL
protein	NULL
A-Sepharose	NULL
or	NULL
protein	NULL
G-Sepharose	NULL
in	NULL
100	NULL
pl	NULL
vol	NULL
was	NULL
then	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
1	NULL
h.	NULL
The	NULL
binding	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
same	NULL
M2	NULL
buffer	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
washed	NULL
six	NULL
times	NULL
each	NULL
with	NULL
1	NULL
ml	NULL
of	NULL
M2	NULL
buffer	NULL
and	NULL
used	NULL
for	NULL
in	NULL
vitro	NULL
kinase	NULL
reactions	NULL
.	NULL

In	NULL
vitro	NULL
assays	NULL
for	NULL
cyclin-dependent	NULL
kinases	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
DTT	NULL
.	NULL

A	NULL
total	NULL
of	NULL
4	NULL
pg	NULL
of	NULL
histone	NULL
H1	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
substrate	NULL
;	NULL
the	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
30	NULL
ul	NULL
and	NULL
contained	NULL
1.25	NULL
pl	NULL
2	NULL
mM	NULL
ATP	NULL
and	NULL
10	NULL
uCi	NULL
of	NULL
[	NULL
y-P	NULL
]	NULL
ATP	NULL
.	NULL

After	NULL
incubation	NULL
at	NULL
37°C	NULL
for	NULL
15	NULL
min	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
boiled	NULL
and	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Histone	NULL
H1	NULL
phosphorylation	NULL
was	NULL
assessed	NULL
by	NULL
autoradiography	NULL
.	NULL

Proliferation	NULL
assays	NULL
Proliferation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
31-33	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
EC	NULL
were	NULL
seeded	NULL
into	NULL
96-well	NULL
flat-bottom	NULL
plates	NULL
at	NULL
5000	NULL
cells/well	NULL
,	NULL
and	NULL
left	NULL
to	NULL
attach	NULL
overnight	NULL
in	NULL
EGM	NULL
.	NULL

After	NULL
18	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
EGM	NULL
was	NULL
removed	NULL
and	NULL
replaced	NULL
with	NULL
EGM	NULL
containing	NULL
5	NULL
%	NULL
FCS	NULL
.	NULL

On	NULL
day	NULL
3	NULL
,	NULL
anti-MHC	NULL
class	NULL
I	NULL
mAbs	NULL
or	NULL
control	NULL
Abs	NULL
(	NULL
10	NULL
pg/ml	NULL
!	NULL
)	NULL

were	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
human	NULL
rbFGF	NULL
(	NULL
0.6	NULL
ng/ml	NULL
)	NULL
,	NULL
Olomoucine	NULL
(	NULL
100	NULL
wM	NULL
)	NULL
,	NULL
and/or	NULL
$	NULL
B203580	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
were	NULL
added	NULL
together	NULL
with	NULL
mAb	NULL
W6/32	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
was	NULL
determined	NULL
by	NULL
detaching	NULL
the	NULL
cells	NULL
with	NULL
0.125	NULL
%	NULL
trypsin/	NULL
HLA	NULL
CLASS	NULL
I-MEDIATED	NULL
CELL	NULL
PROLIFERATION	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Ab	NULL
-	NULL
-	NULL
-	NULL
~	NULL
+	NULL
+	NULL
+	NULL
TPA	NULL
HLA	NULL
TPA	NULL
TPA+HLA	NULL
B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
%	NULL
U	NULL
®	NULL
6	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
P	NULL
Rb	NULL
-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
HLA	NULL
.	NULL

30Min	NULL
1	NULL
Hr	NULL
2Hr	NULL
6	NULL
Hr	NULL
Time	NULL
FIGURE	NULL
1	NULL
.	NULL

HLA	NULL
class	NULL
I	NULL
stimulation	NULL
can	NULL
reverse	NULL
Rb-mediated	NULL
inhibition	NULL
of	NULL
E2F1	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
an	NULL
E2-CAT	NULL
reporter	NULL
along	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
pDCEZFI	NULL
(	NULL
Zanes	NULL
2-7	NULL
)	NULL
;	NULL
cotransfection	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
pCMVRb	NULL
inhibited	NULL
E2F1-mediated	NULL
transcription	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
transfected	NULL
cells	NULL
with	NULL
TPA	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
Rb	NULL
(	NULL
Zane	NULL
6	NULL
)	NULL
;	NULL
stimulation	NULL
with	NULL
an	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
along	NULL
with	NULL
TPA	NULL
could	NULL
effectively	NULL
reverse	NULL
Rb-mediated	NULL
inactivation	NULL
of	NULL
E2F1	NULL
.	NULL

There	NULL
was	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
a	NULL
pSV-gal	NULL
vector	NULL
included	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

B	NULL
,	NULL
Time	NULL
course	NULL
of	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
.	NULL

Jurkat	NULL
cells	NULL
transfected	NULL
as	NULL
above	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
TPA	NULL
and	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

The	NULL
complete	NULL
reversal	NULL
occurs	NULL
6	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

0.05	NULL
%	NULL
EDTA	NULL
,	NULL
harvesting	NULL
,	NULL
and	NULL
scintillation	NULL
counting	NULL
on	NULL
a	NULL
LKB	NULL
Beta	NULL
Plate	NULL
Cell	NULL
Harvester	NULL
.	NULL

All	NULL
data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
cpm	NULL
of	NULL
triplicate	NULL
de-terminations	NULL
.	NULL

The	NULL
stimulation	NULL
index	NULL
was	NULL
calculated	NULL
according	NULL
to	NULL
the	NULL
following	NULL
formula	NULL
:	NULL
(	NULL
mean	NULL
cpm	NULL
of	NULL
triplicate	NULL
determinations	NULL
of	NULL
test/mean	NULL
cpm	NULL
of	NULL
triplicate	NULL
determinations	NULL
of	NULL
control	NULL
cultures	NULL
)	NULL
.	NULL

Results	NULL
HLA	NULL
class	NULL
I	NULL
stimulation	NULL
leads	NULL
to	NULL
Rb	NULL
inactivation	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
Experiments	NULL
were	NULL
designed	NULL
to	NULL
evaluate	NULL
whether	NULL
treatment	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
an	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
could	NULL
inactivate	NULL
Rb	NULL
.	NULL

The	NULL
strategy	NULL
was	NULL
to	NULL
use	NULL
E2F1-mediated	NULL
transcriptional	NULL
activity	NULL
as	NULL
a	NULL
measure	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

Transfection	NULL
of	NULL
an	NULL
E2F1	NULL
expression	NULL
vector	NULL
along	NULL
with	NULL
an	NULL
E2-CAT	NULL
reporter	NULL
construct	NULL
led	NULL
to	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
transcriptional	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
lene	NULL
2	NULL
)	NULL
.	NULL

Cotransfection	NULL
of	NULL
a	NULL
human	NULL
Rb	NULL
expression	NULL
vector	NULL
could	NULL
completely	NULL
inhibit	NULL
E2F	NULL
function	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
as	NULL
has	NULL
been	NULL
found	NULL
in	NULL
various	NULL
other	NULL
cell	NULL
lines	NULL
.	NULL

There	NULL
was	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
E2F	NULL
when	NULL
cells	NULL
transfected	NULL
with	NULL
E2-CAT	NULL
and	NULL
E2F1	NULL
were	NULL
treated	NULL
with	NULL
either	NULL
TPA	NULL
alone	NULL
or	NULL
with	NULL
W6/32	NULL
,	NULL
a	NULL
murine	NULL
mAb	NULL
specific	NULL
for	NULL
a	NULL
nonpolymorphic	NULL
region	NULL
on	NULL
class	NULL
I	NULL
molecules	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
TPA	NULL
treatment	NULL
of	NULL
cells	NULL
cotransfected	NULL
with	NULL
Rb	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
Rb	NULL
function	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
Zane	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
cells	NULL
cotransfected	NULL
with	NULL
Rb	NULL
were	NULL
treated	NULL
with	NULL
a	NULL
combination	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Rb	NULL
*	NULL
+	NULL
+	NULL
+	NULL
+	NULL
HLA	NULL
-	NULL
+	NULL
+	NULL
+	NULL
Inhi	NULL
Olomoucine	NULL
$	NULL
B203580	NULL
B	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Rb	NULL
-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Fas	NULL
*	NULL
*	NULL
*	NULL
+	NULL
*	NULL
Inh	NULL
$	NULL
B203580	NULL
Olomoucine	NULL
FIGURE	NULL
2	NULL
.	NULL

Inactivation	NULL
of	NULL
Rb	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
Fas	NULL
involves	NULL
different	NULL
pathways	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
E2CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
in	NULL
the	NULL
indicated	NULL
lanes	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
transfected	NULL
cells	NULL
with	NULL
HLA	NULL
class	NULL
I	NULL
Ab	NULL
and	NULL
TPA	NULL
reverses	NULL
Rb	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
;	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
200	NULL
wM	NULL
Olomoucine	NULL
during	NULL
stimulation	NULL
abolishes	NULL
inactivation	NULL
of	NULL
Rb	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
.	NULL

HLA	NULL
class	NULL
I	NULL
stimulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
$	NULL
B203580	NULL
,	NULL
a	NULL
p38	NULL
kinase	NULL
inhibitor	NULL
,	NULL
has	NULL
no	NULL
effect	NULL
(	NULL
Zane	NULL
6	NULL
)	NULL
.	NULL

B	NULL
,	NULL
A	NULL
similar	NULL
experiment	NULL
,	NULL
in	NULL
which	NULL
an	NULL
anti-Fas	NULL
Ab	NULL
was	NULL
used	NULL
to	NULL
inactivate	NULL
Rb	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
SB203580	NULL
could	NULL
block	NULL
Rb	NULL
inactivation	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
,	NULL
but	NULL
Olomoucine	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

of	NULL
TPA	NULL
and	NULL
mAb	NULL
W6/32	NULL
,	NULL
Rb-mediated	NULL
repression	NULL
of	NULL
E2F	NULL
activity	NULL
was	NULL
efficiently	NULL
released	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
indicates	NULL
that	NULL
signaling	NULL
pathways	NULL
triggered	NULL
through	NULL
ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
can	NULL
effectively	NULL
overcome	NULL
Rb-mediated	NULL
regulation	NULL
of	NULL
E2F1	NULL
.	NULL

Since	NULL
Rb	NULL
is	NULL
known	NULL
to	NULL
exert	NULL
its	NULL
growth	NULL
regulation	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
targeting	NULL
E2F	NULL
,	NULL
deregulation	NULL
of	NULL
Rb	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
mechanism	NULL
involved	NULL
in	NULL
HLA	NULL
class	NULL
I-mediated	NULL
induction	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
kinetics	NULL
of	NULL
Rb	NULL
inactivation	NULL
,	NULL
a	NULL
similar	NULL
transient	NULL
transfection	NULL
experiment	NULL
was	NULL
conducted	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
but	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
different	NULL
periods	NULL
of	NULL
time	NULL
with	NULL
TPA	NULL
and	NULL
anti-HLA	NULL
Abs	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
E2F-mediated	NULL
transcription	NULL
started	NULL
to	NULL
appear	NULL
2	NULL
h	NULL
after	NULL
anti-HLA	NULL
class	NULL
I	NULL
stimulation	NULL
.	NULL

Full	NULL
reversal	NULL
of	NULL
Rb-mediated	NULL
inhibition	NULL
was	NULL
not	NULL
observed	NULL
until	NULL
after	NULL
6	NULL
h.	NULL
This	NULL
suggests	NULL
that	NULL
HLA	NULL
class	NULL
-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
is	NULL
not	NULL
an	NULL
immediate	NULL
event	NULL
in	NULL
the	NULL
signaling	NULL
pathway	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
Fas-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
occurred	NULL
within	NULL
30	NULL
min	NULL
(	NULL
69	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
different	NULL
signaling	NULL
cascades	NULL
can	NULL
target	NULL
the	NULL
Rb-E2F	NULL
regulatory	NULL
pathway	NULL
through	NULL
different	NULL
molecular	NULL
mechanisms	NULL
.	NULL

5353	NULL
#	NULL
®	NULL
®	NULL
+	NULL
+	NULL
+	NULL
+	NULL
®	NULL
®	NULL
®	NULL
U	NULL
®	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Rb	NULL
-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
HLA	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
inh	NULL
-	NULL
-	NULL
-	NULL
-	NULL
FGF	NULL
PDGF	NULL
-	NULL
TGF	NULL
IgG	NULL
FIGURE	NULL
3	NULL
.	NULL

HLA	NULL
class	NULL
-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
in	NULL
EC	NULL
is	NULL
inhibited	NULL
by	NULL
an	NULL
anti-FGF	NULL
Ab	NULL
.	NULL

A	NULL
,	NULL
EC2709	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
E2-CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Stimulation	NULL
with	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
for	NULL
6	NULL
h	NULL
reversed	NULL
Rb-mediated	NULL
repression	NULL
of	NULL
E2F1	NULL
activity	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Inclusion	NULL
of	NULL
a	NULL
blocking	NULL
Ab	NULL
to	NULL
FGF	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
prevented	NULL
HLA-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
;	NULL
blocking	NULL
Abs	NULL
to	NULL
PDGF	NULL
,	NULL
TGF-B	NULL
,	NULL
or	NULL
a	NULL
normal	NULL
mouse	NULL
IgG	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
lanes	NULL
6-8	NULL
)	NULL
.	NULL

Signaling	NULL
through	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
and	NULL
Fas	NULL
inactivates	NULL
Rb	NULL
by	NULL
different	NULL
mechanisms	NULL
Although	NULL
cyclins	NULL
and	NULL
cyclin-dependent	NULL
kinases	NULL
are	NULL
the	NULL
major	NULL
mediators	NULL
of	NULL
Rb	NULL
inactivation	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
other	NULL
kinases	NULL
such	NULL
as	NULL
the	NULL
p38	NULL
kinase	NULL
can	NULL
efficiently	NULL
inactivate	NULL
Rb	NULL
(	NULL
69	NULL
)	NULL
.	NULL

Efforts	NULL
were	NULL
made	NULL
to	NULL
assess	NULL
whether	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
involves	NULL
cyclin-dependent	NULL
kinases	NULL
or	NULL
occurs	NULL
through	NULL
mechanisms	NULL
independent	NULL
of	NULL
them	NULL
.	NULL

The	NULL
experimental	NULL
design	NULL
was	NULL
to	NULL
transiently	NULL
transfect	NULL
Jurkat	NULL
cells	NULL
with	NULL
E2-CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
,	NULL
and	NULL
stimulate	NULL
the	NULL
cells	NULL
with	NULL
anti-HLA	NULL
Abs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Olomoucine	NULL
,	NULL
which	NULL
is	NULL
a	NULL
cdk	NULL
inhibitor	NULL
,	NULL
or	NULL
$	NULL
B203580	NULL
,	NULL
a	NULL
specific	NULL
inhibitor	NULL
for	NULL
p38	NULL
kinase	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
with	NULL
mAb	NULL
W6/32	NULL
reversed	NULL
Rb-mediated	NULL
inhibition	NULL
of	NULL
E2F	NULL
within	NULL
6	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
Olomoucine	NULL
during	NULL
HLA	NULL
stimulation	NULL
totally	NULL
prevented	NULL
Rb	NULL
inactivation	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Since	NULL
Olomoucine	NULL
is	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
cdk2	NULL
and	NULL
cdc2	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
these	NULL
kinases	NULL
are	NULL
involved	NULL
in	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
.	NULL

Since	NULL
cdk2	NULL
in	NULL
association	NULL
with	NULL
cyclin	NULL
E	NULL
is	NULL
known	NULL
to	NULL
inactivate	NULL
Rb	NULL
during	NULL
growth-factor-	NULL
mediated	NULL
stimulation	NULL
of	NULL
cell	NULL
proliferation	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
same	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
inactivating	NULL
Rb	NULL
in	NULL
response	NULL
to	NULL
HLA	NULL
class	NULL
I	NULL
as	NULL
well	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
p38	NULL
kinase	NULL
inhibitor	NULL
SB203580	NULL
had	NULL
no	NULL
detectable	NULL
effect	NULL
on	NULL
HLA	NULL
class	NULL
-induced	NULL
inactivation	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Fas-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
could	NULL
be	NULL
efficiently	NULL
blocked	NULL
by	NULL
the	NULL
p38	NULL
inhibitor	NULL
,	NULL
but	NULL
not	NULL
Olomoucine	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
(	NULL
69	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
different	NULL
signaling	NULL
pathways	NULL
can	NULL
target	NULL
Rb	NULL
protein	NULL
,	NULL
and	NULL
thus	NULL
E2F	NULL
activity	NULL
through	NULL
the	NULL
mediation	NULL
of	NULL
different	NULL
kinases	NULL
.	NULL

HLA-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
in	NULL
EC	NULL
requires	NULL
FGF	NULL
receptor	NULL
activity	NULL
HLA	NULL
class	NULL
I-mediated	NULL
induction	NULL
of	NULL
cell	NULL
proliferation	NULL
has	NULL
been	NULL
well	NULL
characterized	NULL
in	NULL
primary	NULL
cultures	NULL
of	NULL
human	NULL
EC	NULL
lines	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

As	NULL
described	NULL
earlier	NULL
,	NULL
ligation	NULL
of	NULL
class	NULL
I	NULL
molecules	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
EC	NULL
with	NULL
anti-HLA	NULL
Abs	NULL
results	NULL
in	NULL
increased	NULL
FGF	NULL
receptor	NULL
expression	NULL
,	NULL
enhanced	NULL
ligand	NULL
binding	NULL
,	NULL
and	NULL
augmented	NULL
cell	NULL
proliferation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
inhibition	NULL
of	NULL
FGF	NULL
receptor	NULL
function	NULL
could	NULL
prevent	NULL
HLA	NULL
class	NULL
[	NULL
-induced	NULL
proliferation	NULL
of	NULL
EC	NULL
.	NULL

To	NULL
explore	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
evaluated	NULL
whether	NULL
HLA	NULL
class	NULL
I-mediated	NULL
EC	NULL
proliferation	NULL
involves	NULL
Rb	NULL
inactivation	NULL
and	NULL
whether	NULL
Rb	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
5354	NULL
E2CAT	NULL
+	NULL
E2F1	NULL
>	NULL
-Rb	NULL
HLA	NULL
inh	NULL
-	NULL
-	NULL
°	NULL
soa	NULL
+	NULL
t	NULL
d	NULL
§++++Q	NULL
‘	NULL
14	NULL
+	NULL
+	NULL
+o	NULL
@	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
*	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Rb	NULL
=	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
FGF	NULL
+	NULL
=	NULL
a	NULL
+	NULL
+	NULL
+	NULL
inhi	NULL
-	NULL
=	NULL
-	NULL
=	NULL
cdk	NULL
p38	NULL
HLA	NULL
CLASS	NULL
I-MEDIATED	NULL
CELL	NULL
PROLIFERATION	NULL
B	NULL
HLA	NULL
Stimulation	NULL
k	NULL
>	NULL
P	NULL
I	NULL
£	NULL
.	NULL

ks	NULL
I	NULL
O	NULL
£	NULL
E	NULL
«	NULL
©	NULL
Cyclin	NULL
D	NULL
ﬂ	NULL
Cyclin	NULL
E	NULL
‘	NULL
m	NULL
©	NULL
La	NULL
©	NULL
®	NULL
®	NULL
®	NULL
E2CAT	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
E2F1	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Rb	NULL
*	NULL
=	NULL
+	NULL
+	NULL
+	NULL
+	NULL
HLA	NULL
>	NULL
>	NULL
~~~	NULL
+	NULL
+	NULL
+	NULL
DNCdk	NULL
2	NULL
416	NULL
FIGURE	NULL
4	NULL
.	NULL

HLA	NULL
class	NULL
-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
involves	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

A	NULL
,	NULL
EC2709	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
E2-CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
,	NULL
as	NULL
above	NULL
.	NULL

HLA	NULL
stimulation	NULL
inactivated	NULL
Rb	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
within	NULL
6	NULL
h	NULL
;	NULL
addition	NULL
of	NULL
Olomoucine	NULL
,	NULL
a	NULL
cdk	NULL
inhibitor	NULL
,	NULL
prevented	NULL
this	NULL
inactivation	NULL
(	NULL
Jane	NULL
5	NULL
)	NULL
,	NULL
but	NULL
a	NULL
p38	NULL
inhibitor	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Jane	NULL
6	NULL
)	NULL
.	NULL

B	NULL
,	NULL
Induction	NULL
of	NULL
cyclin	NULL
E-associated	NULL
kinase	NULL
activity	NULL
upon	NULL
HLA	NULL
class	NULL
I	NULL
stimulation	NULL
.	NULL

Extracts	NULL
from	NULL
EC2709	NULL
cells	NULL
prepared	NULL
after	NULL
stimulating	NULL
with	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
Abs	NULL
to	NULL
cyclin	NULL
D	NULL
or	NULL
cyclin	NULL
E.	NULL
The	NULL
kinase	NULL
activity	NULL
was	NULL
assessed	NULL
by	NULL
performing	NULL
an	NULL
in	NULL
vitro	NULL
assay	NULL
using	NULL
histone	NULL
H1	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

Cyclin	NULL
E-associated	NULL
kinase	NULL
activity	NULL
is	NULL
induced	NULL
within	NULL
4	NULL
h	NULL
of	NULL
stimulation	NULL
,	NULL
but	NULL
there	NULL
is	NULL
no	NULL
change	NULL
in	NULL
kinase	NULL
activity	NULL
associated	NULL
with	NULL
cyclin	NULL
D.	NULL
C	NULL
,	NULL
A	NULL
similar	NULL
experiment	NULL
as	NULL
in	NULL
A	NULL
,	NULL
but	NULL
0.6	NULL
ng/m	NULL
!	NULL

of	NULL
bFGF	NULL
was	NULL
used	NULL
to	NULL
stimulate	NULL
the	NULL
cells	NULL
for	NULL
6	NULL
h	NULL
instead	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
Ab	NULL
.	NULL

BFGF	NULL
could	NULL
inactivate	NULL
Rb	NULL
by	NULL
itself	NULL
efficiently	NULL
(	NULL
Jane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
it	NULL
was	NULL
inhibited	NULL
by	NULL
Olomoucine	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
,	NULL
but	NULL
not	NULL
$	NULL
B203580	NULL
.	NULL

D	NULL
,	NULL
A	NULL
dominant-negative	NULL
cdk2	NULL
construct	NULL
can	NULL
prevent	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
.	NULL

EC2709	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
E2-CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
.	NULL

A	NULL
dominant-negative	NULL
edk2	NULL
construct	NULL
(	NULL
6	NULL
ug	NULL
;	NULL
lane	NULL
5	NULL
)	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
cdk4	NULL
and	NULL
cdk6	NULL
(	NULL
6	NULL
ug	NULL
each	NULL
;	NULL
lane	NULL
6	NULL
)	NULL
was	NULL
cotransfected	NULL
as	NULL
indicated	NULL
;	NULL
stimulation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
inactivates	NULL
Rb	NULL
(	NULL
Zane	NULL
4	NULL
)	NULL
,	NULL
but	NULL
this	NULL
is	NULL
blocked	NULL
by	NULL
the	NULL
dominant-negative	NULL
cdk2	NULL
,	NULL
but	NULL
not	NULL
cdk4/6	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

inactivation	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
bFGF	NULL
to	NULL
EC	NULL
.	NULL

For	NULL
these	NULL
experiments	NULL
,	NULL
EC	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
E2CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
,	NULL
followed	NULL
by	NULL
stimulation	NULL
with	NULL
mAb	NULL
W6/32	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
results	NULL
obtained	NULL
using	NULL
Jurkat	NULL
cells	NULL
,	NULL
Rb-mediated	NULL
repression	NULL
of	NULL
E2F1	NULL
activity	NULL
in	NULL
EC	NULL
could	NULL
be	NULL
efficiently	NULL
reversed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
W6/32	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
HLA-mediated	NULL
modulation	NULL
of	NULL
Rb	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
one	NULL
particular	NULL
cell	NULL
line	NULL
or	NULL
cell	NULL
lineage	NULL
.	NULL

Since	NULL
ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
is	NULL
known	NULL
to	NULL
induce	NULL
proliferation	NULL
in	NULL
EC	NULL
,	NULL
and	NULL
since	NULL
Rb	NULL
inactivation	NULL
correlates	NULL
with	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
targets	NULL
the	NULL
Rb	NULL
protein	NULL
to	NULL
facilitate	NULL
cell	NULL
division	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
FGF	NULL
receptor	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
inactivation	NULL
of	NULL
Rb	NULL
,	NULL
the	NULL
transfected	NULL
EC	NULL
were	NULL
treated	NULL
with	NULL
mAb	NULL
W6/32	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
neutralizing	NULL
Abs	NULL
to	NULL
bFGF	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
neutralizing	NULL
anti-bFGF	NULL
Abs	NULL
rendered	NULL
HLA	NULL
class	NULL
I-mediated	NULL
signaling	NULL
ineffective	NULL
in	NULL
reversing	NULL
Rb	NULL
function	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
neutralizing	NULL
Abs	NULL
to	NULL
other	NULL
growth	NULL
factors	NULL
produced	NULL
by	NULL
EC	NULL
,	NULL
such	NULL
as	NULL
PDGF	NULL
and	NULL
TGF-	NULL
$	NULL
,	NULL
or	NULL
isotype	NULL
control	NULL
Abs	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
6-8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
requires	NULL
FGF	NULL
receptor	NULL
ligand	NULL
binding	NULL
.	NULL

It	NULL
thus	NULL
appears	NULL
that	NULL
the	NULL
FGF	NULL
receptor	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
inactivating	NULL
Rb	NULL
,	NULL
a	NULL
finding	NULL
that	NULL
is	NULL
consistent	NULL
with	NULL
our	NULL
previous	NULL
studies	NULL
showing	NULL
that	NULL
the	NULL
FGF	NULL
receptor	NULL
plays	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
mediating	NULL
HLA	NULL
class	NULL
I-induced	NULL
proliferative	NULL
signals	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

HLA	NULL
class	NULL
I-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
correlates	NULL
with	NULL
enhancement	NULL
of	NULL
cyclin	NULL
E-dependent	NULL
kinase	NULL
activity	NULL
We	NULL
attempted	NULL
to	NULL
examine	NULL
whether	NULL
reversal	NULL
of	NULL
RB	NULL
function	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
ligation	NULL
in	NULL
EC	NULL
can	NULL
also	NULL
be	NULL
blocked	NULL
by	NULL
Olomoucine	NULL
,	NULL
as	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
Olomoucine	NULL
was	NULL
quite	NULL
effective	NULL
in	NULL
blocking	NULL
HLA	NULL
class	NULL
I-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
,	NULL
but	NULL
the	NULL
p38	NULL
kinase	NULL
inhibitor	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
HLA	NULL
class	NULL
I-mediated	NULL
modulation	NULL
of	NULL
Rb	NULL
function	NULL
involves	NULL
the	NULL
same	NULL
downstream	NULL
kinases	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
EC	NULL
cells	NULL
.	NULL

As	NULL
demonstrated	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
above	NULL
,	NULL
HLA	NULL
class	NULL
I-mediated	NULL
cell	NULL
proliferation	NULL
requires	NULL
the	NULL
involvement	NULL
of	NULL
bFGF	NULL
receptors	NULL
;	NULL
hence	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
bFGF-induced	NULL
cell	NULL
proliferation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
Olomoucine	NULL
as	NULL
well	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
stimulation	NULL
of	NULL
the	NULL
EC	NULL
with	NULL
bFGF	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
Ab	NULL
resulted	NULL
in	NULL
an	NULL
effective	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

This	NULL
FGF-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
could	NULL
be	NULL
blocked	NULL
by	NULL
the	NULL
cdk	NULL
inhibitor	NULL
Olomoucine	NULL
,	NULL
but	NULL
not	NULL
the	NULL
p38	NULL
inhibitor	NULL
SB203580	NULL
,	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
.	NULL

Since	NULL
inactivation	NULL
of	NULL
Rb	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
Olomoucine	NULL
in	NULL
two	NULL
different	NULL
cell	NULL
lines	NULL
,	NULL
experiments	NULL
were	NULL
designed	NULL
to	NULL
examine	NULL
whether	NULL
the	NULL
activity	NULL
of	NULL
cdks	NULL
,	NULL
which	NULL
are	NULL
the	NULL
targets	NULL
of	NULL
Olomoucine	NULL
,	NULL
changes	NULL
upon	NULL
ligation	NULL
of	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

The	NULL
strategy	NULL
was	NULL
to	NULL
prepare	NULL
extracts	NULL
from	NULL
cells	NULL
stimulated	NULL
with	NULL
an	NULL
anti-HLA	NULL
Ab	NULL
and	NULL
immunoprecipitate	NULL
cyclin	NULL
D	NULL
and	NULL
cyclin	NULL
E.	NULL
Immunoprecipitations	NULL
were	NULL
conducted	NULL
under	NULL
conditions	NULL
in	NULL
which	NULL
the	NULL
cyclin-cdk	NULL
complexes	NULL
are	NULL
not	NULL
disrupted	NULL
.	NULL

The	NULL
immunoprecipitated	NULL
cyclin-ecdk	NULL
complexes	NULL
were	NULL
used	NULL
to	NULL
conduct	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
using	NULL
histone	NULL
H1	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
treatment	NULL
of	NULL
EC	NULL
with	NULL
anti-HLA	NULL
Abs	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
cyclin	NULL
D-dependent	NULL
kinase	NULL
activity	NULL
at	NULL
the	NULL
same	NULL
time	NULL
points	NULL
when	NULL
Rb	NULL
was	NULL
inactivated	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
cyclin	NULL
D-cdk4/6	NULL
complexes	NULL
do	NULL
not	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
Rb	NULL
inactivation	NULL
in	NULL
response	NULL
to	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
we	NULL
find	NULL
that	NULL
there	NULL
is	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
kinases	NULL
associated	NULL
with	NULL
cyclin	NULL
E	NULL
within	NULL
4	NULL
h	NULL
of	NULL
HLA	NULL
stimulation	NULL
.	NULL

Since	NULL
cyclin	NULL
E-cdk2	NULL
complexes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
phosphorylate	NULL
Rb	NULL
,	NULL
and	NULL
since	NULL
Olomoucine	NULL
can	NULL
efficiently	NULL
inhibit	NULL
cdk2	NULL
,	NULL
but	NULL
not	NULL
cdk4/6	NULL
,	NULL
it	NULL
appears	NULL
likely	NULL
that	NULL
the	NULL
inactivation	NULL
of	NULL
Rb	NULL
in	NULL
response	NULL
to	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
occurs	NULL
through	NULL
the	NULL
mediation	NULL
of	NULL
this	NULL
kinase	NULL
.	NULL

This	NULL
possibility	NULL
was	NULL
verified	NULL
by	NULL
a	NULL
transient	NULL
transfection	NULL
experiment	NULL
in	NULL
which	NULL
EC	NULL
were	NULL
transfected	NULL
with	NULL
E2CAT	NULL
,	NULL
E2F1	NULL
,	NULL
and	NULL
Rb	NULL
.	NULL

The	NULL
aim	NULL
of	NULL
this	NULL
experiment	NULL
was	NULL
to	NULL
determine	NULL
whether	NULL
dominant-negative	NULL
cdk2	NULL
or	NULL
edek4/6	NULL
could	NULL
block	NULL
HLA	NULL
class	NULL
I-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4D	NULL
,	NULL
overexpression	NULL
of	NULL
a	NULL
dominant-negative	NULL
edk2	NULL
could	NULL
block	NULL
HLA	NULL
class	NULL
I-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

Since	NULL
edk2	NULL
is	NULL
known	NULL
to	NULL
function	NULL
in	NULL
association	NULL
with	NULL
cyclin	NULL
E	NULL
,	NULL
it	NULL
confirms	NULL
the	NULL
role	NULL
for	NULL
cyclin	NULL
E-associated	NULL
kinases	NULL
in	NULL
mediating	NULL
HLA	NULL
class	NULL
-induced	NULL
proliferative	NULL
signals	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
overexpression	NULL
of	NULL
dominant-negative	NULL
cdk4	NULL
and	NULL
cdk6	NULL
,	NULL
which	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
cyclin	NULL
D-associated	NULL
kinases	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
of	NULL
HLA	NULL
class	NULL
I-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
.	NULL

Olomoucine	NULL
,	NULL
but	NULL
not	NULL
SB203580	NULL
,	NULL
blocks	NULL
HLA	NULL
class	NULL
-mediated	NULL
cell	NULL
proliferation	NULL
Since	NULL
we	NULL
found	NULL
that	NULL
different	NULL
kinases	NULL
are	NULL
involved	NULL
in	NULL
Fas-mediated	NULL
and	NULL
HLA	NULL
class	NULL
I-mediated	NULL
reversal	NULL
of	NULL
Rb	NULL
function	NULL
,	NULL
attempts	NULL
were	NULL
made	NULL
to	NULL
assess	NULL
which	NULL
kinases	NULL
are	NULL
involved	NULL
in	NULL
class	NULL
I	NULL
induction	NULL
of	NULL
cell	NULL
proliferation	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
ligation	NULL
of	NULL
class	NULL
I	NULL
molecules	NULL
with	NULL
mAb	NULL
W6/32	NULL
could	NULL
stimulate	NULL
S-phase	NULL
entry	NULL
within	NULL
24	NULL
h	NULL
in	NULL
growth	NULL
factor-deprived	NULL
EC	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
tritiated	NULL
thymidine	NULL
incorporation	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
p38	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
HLA	NULL
class	NULL
I-mediated	NULL
growth	NULL
induction	NULL
,	NULL
or	NULL
whether	NULL
the	NULL
entire	NULL
class	NULL
-mediated	NULL
signaling	NULL
occurs	NULL
through	NULL
cyclin-dependent	NULL
kinases	NULL
,	NULL
EC	NULL
were	NULL
treated	NULL
with	NULL
mAb	NULL
W6/32	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Olomoucine	NULL
or	NULL
$	NULL
B203580	NULL
,	NULL
the	NULL
p38	NULL
inhibitor	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
Olomoucine	NULL
totally	NULL
eliminated	NULL
HLA	NULL
class	NULL
I-mediated	NULL
S-phase	NULL
entry	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
SB203580	NULL
did	NULL
not	NULL
inhibit	NULL
cell	NULL
proliferation	NULL
and	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
augmented	NULL
W6/32-induced	NULL
proliferation	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
HLA	NULL
class	NULL
I-induced	NULL
cell	NULL
proliferation	NULL
is	NULL
primarily	NULL
regulated	NULL
by	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

Additional	NULL
experiments	NULL
were	NULL
conducted	NULL
in	NULL
which	NULL
bFGF	NULL
was	NULL
used	NULL
to	NULL
induce	NULL
cell	NULL
proliferation	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
anti-HLA	NULL
class	NULL
I	NULL
Abs	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
bFGFE-induced	NULL
cell	NULL
proliferation	NULL
was	NULL
augmented	NULL
by	NULL
costimulation	NULL
with	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
Ab	NULL
W6/32	NULL
.	NULL

Olo-	NULL
5355	NULL
moucine	NULL
efficiently	NULL
inhibited	NULL
the	NULL
combined	NULL
proliferative	NULL
effects	NULL
of	NULL
bFGF	NULL
receptor	NULL
and	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
,	NULL
whereas	NULL
$	NULL
B203580	NULL
enhanced	NULL
the	NULL
proliferative	NULL
effects	NULL
of	NULL
bFGF	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
Abs	NULL
to	NULL
HLA	NULL
class	NULL
I	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
there	NULL
is	NULL
a	NULL
close	NULL
parallel	NULL
between	NULL
HLA	NULL
class	NULL
I-mediated	NULL
induction	NULL
of	NULL
cell	NULL
proliferation	NULL
and	NULL
its	NULL
effects	NULL
on	NULL
Rb	NULL
function	NULL
,	NULL
suggesting	NULL
that	NULL
Rb	NULL
inactivation	NULL
is	NULL
a	NULL
vital	NULL
component	NULL
of	NULL
HLA	NULL
class	NULL
I-mediated	NULL
proliferation	NULL
.	NULL

Discussion	NULL
HLA	NULL
class	NULL
I	NULL
Ag	NULL
signaling	NULL
pathways	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
proliferation	NULL
of	NULL
vascular	NULL
EC	NULL
,	NULL
SMC	NULL
,	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
apoptosis	NULL
of	NULL
activated	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
(	NULL
31-33	NULL
,	NULL
36-47	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
mechanisms	NULL
and	NULL
molecules	NULL
involved	NULL
in	NULL
the	NULL
HLA-mediated	NULL
apoptosis	NULL
are	NULL
emerging	NULL
,	NULL
such	NULL
information	NULL
is	NULL
scanty	NULL
on	NULL
HLA	NULL
class	NULL
-mediated	NULL
cell	NULL
proliferation	NULL
.	NULL

The	NULL
studies	NULL
described	NULL
in	NULL
this	NULL
work	NULL
attempt	NULL
to	NULL
elucidate	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
the	NULL
cell	NULL
cycle	NULL
machinery	NULL
is	NULL
manipulated	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
.	NULL

We	NULL
were	NULL
able	NULL
to	NULL
focus	NULL
specifically	NULL
on	NULL
the	NULL
cell	NULL
proliferation	NULL
aspect	NULL
because	NULL
the	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
used	NULL
in	NULL
this	NULL
study	NULL
does	NULL
not	NULL
induce	NULL
apoptosis	NULL
(	NULL
31-33	NULL
,	NULL
38	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Attention	NULL
was	NULL
focused	NULL
on	NULL
Rb	NULL
protein	NULL
and	NULL
its	NULL
downstream	NULL
target	NULL
,	NULL
the	NULL
E2F	NULL
transcription	NULL
factor	NULL
,	NULL
for	NULL
two	NULL
reasons	NULL
:	NULL
first	NULL
,	NULL
Rb	NULL
is	NULL
the	NULL
main	NULL
regulator	NULL
of	NULL
G	NULL
,	NULL
/S	NULL
transition	NULL
in	NULL
mammalian	NULL
cells	NULL
(	NULL
5	NULL
,	NULL
10	NULL
)	NULL
;	NULL
second	NULL
,	NULL
we	NULL
had	NULL
observed	NULL
that	NULL
various	NULL
signaling	NULL
pathways	NULL
target	NULL
the	NULL
Rb	NULL
protein	NULL
,	NULL
whether	NULL
the	NULL
signals	NULL
are	NULL
proliferative	NULL
or	NULL
apoptotic	NULL
.	NULL

As	NULL
mentioned	NULL
in	NULL
the	NULL
introduction	NULL
,	NULL
we	NULL
had	NULL
observed	NULL
that	NULL
Fas-mediated	NULL
signaling	NULL
in	NULL
Jurkat	NULL
cells	NULL
leads	NULL
to	NULL
Rb	NULL
inactivation	NULL
,	NULL
contributing	NULL
to	NULL
apoptosis	NULL
.	NULL

This	NULL
occurs	NULL
through	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
p38	NULL
kinase	NULL
(	NULL
69	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
inhibitors	NULL
of	NULL
p38	NULL
kinase	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
inactivation	NULL
of	NULL
Rb	NULL
following	NULL
ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
with	NULL
anti-HLA	NULL
Abs	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
different	NULL
signaling	NULL
cascades	NULL
can	NULL
target	NULL
Rb	NULL
by	NULL
using	NULL
different	NULL
cellular	NULL
kinases	NULL
,	NULL
with	NULL
the	NULL
end	NULL
result	NULL
in	NULL
one	NULL
situation	NULL
being	NULL
apoptosis	NULL
and	NULL
the	NULL
other	NULL
,	NULL
proliferation	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
Rb	NULL
inactivation	NULL
is	NULL
also	NULL
different	NULL
for	NULL
the	NULL
two	NULL
signaling	NULL
pathways	NULL
:	NULL
whereas	NULL
Fas	NULL
inactivates	NULL
Rb	NULL
within	NULL
30	NULL
min	NULL
,	NULL
HLA	NULL
class	NULL
I	NULL
stimulation	NULL
leads	NULL
to	NULL
a	NULL
partial	NULL
inactivation	NULL
within	NULL
2	NULL
h	NULL
,	NULL
and	NULL
complete	NULL
inactivation	NULL
within	NULL
4-6	NULL
h.	NULL
Since	NULL
we	NULL
have	NULL
observed	NULL
that	NULL
p38	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
inactivating	NULL
Rb	NULL
in	NULL
response	NULL
to	NULL
Fas	NULL
,	NULL
it	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
see	NULL
whether	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
Abs	NULL
that	NULL
induce	NULL
cellular	NULL
apoptosis	NULL
in	NULL
Jurkat	NULL
cells	NULL
affect	NULL
Rb	NULL
through	NULL
p38	NULL
kinase	NULL
.	NULL

As	NULL
described	NULL
earlier	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
stimulation	NULL
on	NULL
EC	NULL
and	NULL
SMC	NULL
were	NULL
conducted	NULL
with	NULL
the	NULL
intention	NULL
of	NULL
assessing	NULL
the	NULL
role	NULL
of	NULL
anti-HLA	NULL
Abs	NULL
in	NULL
the	NULL
development	NULL
of	NULL
transplant-related	NULL
atherosclerosis	NULL
.	NULL

We	NULL
had	NULL
reported	NULL
previously	NULL
that	NULL
ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
with	NULL
anti-HLA	NULL
Abs	NULL
stimulates	NULL
the	NULL
proliferation	NULL
of	NULL
EC	NULL
,	NULL
along	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
cellular	NULL
proteins	NULL
,	NULL
inositol	NULL
phosphate	NULL
generation	NULL
,	NULL
and	NULL
specific	NULL
induction	NULL
of	NULL
the	NULL
FGF	NULL
receptor	NULL
(	NULL
31-33	NULL
)	NULL
.	NULL

HLA	NULL
class	NULL
I-mediated	NULL
proliferation	NULL
could	NULL
be	NULL
prevented	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
neutralizing	NULL
Abs	NULL
to	NULL
bFGF	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
FGF	NULL
receptor	NULL
is	NULL
a	NULL
major	NULL
core-ceptor	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
HLA	NULL
class	NULL
-mediated	NULL
signals	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
find	NULL
that	NULL
HLA	NULL
class	NULL
I	NULL
stimulation	NULL
can	NULL
inactivate	NULL
the	NULL
Rb	NULL
protein	NULL
,	NULL
and	NULL
this	NULL
could	NULL
be	NULL
inhibited	NULL
efficiently	NULL
by	NULL
a	NULL
neutralizing	NULL
Ab	NULL
to	NULL
bFGF	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
inactivation	NULL
of	NULL
Rb	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
is	NULL
a	NULL
vital	NULL
step	NULL
in	NULL
induction	NULL
of	NULL
cell	NULL
proliferation	NULL
,	NULL
and	NULL
occurs	NULL
subsequent	NULL
to	NULL
FGF	NULL
receptor-mediated	NULL
signaling	NULL
.	NULL

The	NULL
current	NULL
results	NULL
also	NULL
support	NULL
our	NULL
earlier	NULL
observations	NULL
that	NULL
the	NULL
FGF	NULL
receptor	NULL
is	NULL
required	NULL
for	NULL
transducing	NULL
HLA	NULL
class	NULL
I-mediated	NULL
proliferative	NULL
signals	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
bFGF	NULL
receptor	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
are	NULL
not	NULL
clear	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
links	NULL
between	NULL
bFGF	NULL
receptor	NULL
and	NULL
cyclin	NULL
E-cdk2	NULL
activation	NULL
remain	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
5356	NULL
STIMULATION	NULL
INDEX	NULL
24	NULL
H	NULL
0	NULL
U	NULL
RS	NULL
_	NULL
STIMULATION	NULL
INDEX	NULL
o	NULL
24	NULL
H	NULL
O	NULL
U	NULL
RS	NULL
HLA	NULL
CLASS	NULL
I-MEDIATED	NULL
CELL	NULL
PROLIFERATION	NULL
tw	NULL
6132	NULL
MIO	NULL
L	NULL
0	NULL
M	NULL
0	NULL
U	NULL
C	NULL
IN	NULL
E	NULL
ms	NULL
B	NULL
203	NULL
6	NULL
8	NULL
0	NULL
EAW	NULL
8132	NULL
+	NULL
0	NULL
L	NULL
O	NULL
MU	NULL
CIN	NULL
E	NULL
a/22+5	NULL
8	NULL
203	NULL
68	NULL
0	NULL
Cleror	NULL
REW	NULL
6/32	NULL
+	NULL
bF	NULL
OF	NULL
W	NULL
6/32	NULL
+B	NULL
ro	NULL
F	NULL
+0	NULL
L	NULL
O	NULL
M	NULL
0	NULL
U	NULL
C	NULL
IN	NULL
E	NULL
e/s2	NULL
+	NULL
bFGF	NULL
+	NULL
s	NULL
B	NULL
203680	NULL
mbrGF	NULL
+	NULL
0	NULL
LO	NULL
M	NULL
0	NULL
U	NULL
CINE	NULL
+	NULL
8B203680	NULL
sss	NULL
FIGURE	NULL
5	NULL
.	NULL

Effect	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
on	NULL
HLA	NULL
class	NULL
-induced	NULL
proliferation	NULL
of	NULL
EC	NULL
.	NULL

A	NULL
,	NULL
Quiescent	NULL
EC2709	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
ug/tal	NULL
of	NULL
W6/32	NULL
anti-HLA	NULL
class	NULL
I	NULL
Ab	NULL
,	NULL
100	NULL
M	NULL
Olomoucine	NULL
,	NULL
10	NULL
uM	NULL
$	NULL
B203580	NULL
,	NULL
10	NULL
ug/ml	NULL
W6/32	NULL
+	NULL
100	NULL
mM	NULL
Olomoucine	NULL
,	NULL
or	NULL
10	NULL
ug/ml	NULL
W6/32	NULL
+	NULL
10	NULL
uM	NULL
$	NULL
B203580	NULL
.	NULL

B	NULL
,	NULL
Quiescent	NULL
EC2709	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
0.6	NULL
ng/ml	NULL
bFGF	NULL
,	NULL
10	NULL
ug/ml	NULL
W6/32	NULL
+	NULL
0.6	NULL
ng/ml	NULL
bFGF	NULL
,	NULL
10	NULL
ug/ml	NULL
W6/32	NULL
+	NULL
0.6	NULL
ng/ml	NULL
bFGF	NULL
+	NULL
100	NULL
uM	NULL
Olomoucine	NULL
,	NULL
or	NULL
10	NULL
ug/ml	NULL
W6/32	NULL
+	NULL
0.6	NULL
ng/ml	NULL
bFGF	NULL
+	NULL
10	NULL
M	NULL
S	NULL
$	NULL
B203580	NULL
.	NULL

Proliferation	NULL
was	NULL
assessed	NULL
by	NULL
measuring	NULL
[	NULL
°H|thymidine	NULL
incorporation	NULL
after	NULL
24	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

The	NULL
data	NULL
are	NULL
expressed	NULL
as	NULL
stimulation	NULL
index	NULL
:	NULL
mean	NULL
cpm	NULL
of	NULL
triplicate	NULL
determinations	NULL
(	NULL
SD	NULL
<	NULL
10	NULL
%	NULL
)	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
mAb	NULL
,	NULL
inhibitors	NULL
,	NULL
and/or	NULL
bFGF	NULL
divided	NULL
by	NULL
the	NULL
mean	NULL
cpm	NULL
of	NULL
triplicate	NULL
determinations	NULL
(	NULL
SD	NULL
<	NULL
10	NULL
%	NULL
)	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
normal	NULL
mouse	NULL
IgG	NULL
.	NULL

One	NULL
of	NULL
four	NULL
representative	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

to	NULL
be	NULL
elucidated	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
Raf-1	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
HLA	NULL
class	NULL
-mediated	NULL
inactivation	NULL
of	NULL
Rb	NULL
also	NULL
,	NULL
as	NULL
we	NULL
had	NULL
shown	NULL
previously	NULL
for	NULL
serum	NULL
stimulation	NULL
of	NULL
quiescent	NULL
human	NULL
diploid	NULL
fibroblasts	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Although	NULL
this	NULL
would	NULL
provide	NULL
an	NULL
additional	NULL
link	NULL
between	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
and	NULL
Rb	NULL
,	NULL
preliminary	NULL
experiments	NULL
did	NULL
not	NULL
show	NULL
any	NULL
alterations	NULL
in	NULL
the	NULL
Rb/Raf-1	NULL
interaction	NULL
in	NULL
EC	NULL
cells	NULL
upon	NULL
HLA	NULL
class	NULL
I	NULL
ligation	NULL
.	NULL

This	NULL
needs	NULL
further	NULL
detailed	NULL
investigation	NULL
,	NULL
but	NULL
as	NULL
of	NULL
now	NULL
we	NULL
do	NULL
not	NULL
have	NULL
evidence	NULL
for	NULL
such	NULL
a	NULL
direct	NULL
link	NULL
through	NULL
the	NULL
Raf-1	NULL
molecule	NULL
.	NULL

This	NULL
is	NULL
not	NULL
surprising	NULL
,	NULL
since	NULL
the	NULL
cell	NULL
lines	NULL
used	NULL
as	NULL
well	NULL
as	NULL
the	NULL
stimulus	NULL
involved	NULL
are	NULL
qualitatively	NULL
different	NULL
from	NULL
our	NULL
earlier	NULL
study	NULL
on	NULL
HSF-8	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Our	NULL
studies	NULL
also	NULL
show	NULL
that	NULL
the	NULL
p38	NULL
kinase	NULL
plays	NULL
no	NULL
role	NULL
in	NULL
Rb	NULL
inactivation	NULL
in	NULL
response	NULL
to	NULL
HLA	NULL
class	NULL
I-mediated	NULL
signaling	NULL
in	NULL
both	NULL
Jurkat	NULL
as	NULL
well	NULL
as	NULL
EC	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
observation	NULL
that	NULL
the	NULL
p38	NULL
kinase	NULL
inhibitor	NULL
,	NULL
SB203580	NULL
,	NULL
augments	NULL
cell	NULL
proliferation	NULL
in	NULL
collaboration	NULL
with	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
bFGF	NULL
is	NULL
intriguing	NULL
.	NULL

Although	NULL
the	NULL
p38	NULL
kinase	NULL
can	NULL
have	NULL
proliferative	NULL
effects	NULL
in	NULL
some	NULL
cases	NULL
(	NULL
48	NULL
)	NULL
,	NULL
it	NULL
is	NULL
normally	NULL
induced	NULL
in	NULL
response	NULL
to	NULL
cytokines	NULL
and	NULL
other	NULL
signals	NULL
that	NULL
have	NULL
antiproliferative	NULL
effects	NULL
(	NULL
49	NULL
,	NULL
50	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
activation	NULL
of	NULL
the	NULL
p38	NULL
kinase	NULL
correlates	NULL
with	NULL
,	NULL
and	NULL
probably	NULL
contributes	NULL
to	NULL
,	NULL
cellular	NULL
differentiation	NULL
(	NULL
51	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
$	NULL
B203580	NULL
is	NULL
negating	NULL
such	NULL
growth-inhibitory	NULL
influences	NULL
associated	NULL
with	NULL
p38	NULL
kinase	NULL
,	NULL
facilitating	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Such	NULL
a	NULL
collaborative	NULL
induction	NULL
may	NULL
not	NULL
be	NULL
readily	NULL
visible	NULL
when	NULL
cells	NULL
are	NULL
stimulated	NULL
with	NULL
agents	NULL
that	NULL
induce	NULL
multiple	NULL
pathways	NULL
,	NULL
since	NULL
p38	NULL
activity	NULL
is	NULL
probably	NULL
compromised	NULL
by	NULL
other	NULL
means	NULL
.	NULL

Studies	NULL
from	NULL
different	NULL
laboratories	NULL
have	NULL
shown	NULL
that	NULL
proliferative	NULL
signals	NULL
from	NULL
a	NULL
variety	NULL
of	NULL
receptors	NULL
target	NULL
the	NULL
Rb	NULL
protein	NULL
through	NULL
the	NULL
mediation	NULL
of	NULL
cyclin	NULL
D	NULL
and	NULL
associated	NULL
kinases	NULL
.	NULL

Indeed	NULL
,	NULL
it	NULL
had	NULL
been	NULL
suggested	NULL
that	NULL
phosphorylation	NULL
by	NULL
kinases	NULL
associated	NULL
with	NULL
cyclins	NULL
D	NULL
and	NULL
E	NULL
is	NULL
required	NULL
for	NULL
inactivating	NULL
Rb	NULL
in	NULL
response	NULL
to	NULL
serum	NULL
stimulation	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
signaling	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
molecule	NULL
is	NULL
the	NULL
first	NULL
instance	NULL
in	NULL
which	NULL
Rb	NULL
is	NULL
found	NULL
to	NULL
be	NULL
inactivated	NULL
mainly	NULL
through	NULL
cyclin	NULL
E	NULL
and	NULL
associated	NULL
kinases	NULL
.	NULL

As	NULL
our	NULL
results	NULL
clearly	NULL
indicate	NULL
,	NULL
there	NULL
is	NULL
only	NULL
minimal	NULL
involvement	NULL
,	NULL
if	NULL
any	NULL
at	NULL
all	NULL
,	NULL
of	NULL
cyclin	NULL
D	NULL
and	NULL
associated	NULL
kinases	NULL
in	NULL
HLA-mediated	NULL
growth	NULL
induction	NULL
.	NULL

It	NULL
is	NULL
not	NULL
clear	NULL
whether	NULL
cyclin	NULL
E-cdk2	NULL
complex	NULL
alone	NULL
can	NULL
inactivate	NULL
Rb	NULL
;	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
other	NULL
kinases	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
.	NULL

For	NULL
example	NULL
,	NULL
our	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
Raf-1	NULL
can	NULL
physically	NULL
interact	NULL
with	NULL
Rb	NULL
and	NULL
inactivate	NULL
it	NULL
.	NULL

The	NULL
role	NULL
of	NULL
such	NULL
additional	NULL
kinases	NULL
in	NULL
HLA	NULL
class	NULL
I-mediated	NULL
signaling	NULL
pathways	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

From	NULL
another	NULL
angle	NULL
,	NULL
the	NULL
observation	NULL
that	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
cyclin	NULL
E-associated	NULL
kinase	NULL
activity	NULL
is	NULL
induced	NULL
by	NULL
ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
could	NULL
be	NULL
significant	NULL
in	NULL
itself	NULL
.	NULL

It	NULL
had	NULL
been	NULL
demonstrated	NULL
that	NULL
cyclin	NULL
E/edk2	NULL
can	NULL
induce	NULL
cell	NULL
proliferation	NULL
by	NULL
pathways	NULL
that	NULL
are	NULL
independent	NULL
of	NULL
Rb	NULL
and	NULL
E2F	NULL
(	NULL
53	NULL
,	NULL
54	NULL
)	NULL
,	NULL
but	NULL
such	NULL
additional	NULL
pathways	NULL
remain	NULL
elusive	NULL
.	NULL

This	NULL
might	NULL
mean	NULL
that	NULL
HLA	NULL
class	NULL
I	NULL
signaling	NULL
could	NULL
possibly	NULL
affect	NULL
other	NULL
cell	NULL
cycle	NULL
regulatory	NULL
molecules	NULL
also	NULL
,	NULL
which	NULL
are	NULL
targeted	NULL
by	NULL
cyclin	NULL
E/cdk2	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
the	NULL
results	NULL
described	NULL
in	NULL
this	NULL
study	NULL
have	NULL
implications	NULL
for	NULL
the	NULL
role	NULL
of	NULL
class	NULL
I	NULL
signaling	NULL
in	NULL
chronic	NULL
allograft	NULL
rejection	NULL
.	NULL

The	NULL
histologic	NULL
appearance	NULL
of	NULL
transplant	NULL
atherosclerosis	NULL
shows	NULL
marked	NULL
proliferation	NULL
and	NULL
hyperplasia	NULL
of	NULL
vascular	NULL
SMC	NULL
and	NULL
EC	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
augmented	NULL
EC	NULL
and	NULL
SMC	NULL
responsiveness	NULL
to	NULL
growth	NULL
factors	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Indeed	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
identified	NULL
increased	NULL
expression	NULL
of	NULL
several	NULL
SMC	NULL
and	NULL
EC	NULL
growth	NULL
factors	NULL
such	NULL
as	NULL
PDGF	NULL
and	NULL
FGF	NULL
and	NULL
their	NULL
receptors	NULL
in	NULL
areas	NULL
of	NULL
intimal	NULL
hyperplasia	NULL
in	NULL
chronically	NULL
rejected	NULL
heart	NULL
and	NULL
renal	NULL
allografts	NULL
(	NULL
55-58	NULL
)	NULL
.	NULL

Another	NULL
consistent	NULL
finding	NULL
in	NULL
graft	NULL
atherosclerotic	NULL
lesions	NULL
is	NULL
the	NULL
demonstration	NULL
of	NULL
Ig	NULL
deposits	NULL
in	NULL
affected	NULL
vessel	NULL
walls	NULL
and	NULL
within	NULL
the	NULL
media	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
numerous	NULL
studies	NULL
have	NULL
found	NULL
that	NULL
the	NULL
development	NULL
of	NULL
anti-HLA	NULL
Abs	NULL
following	NULL
transplantation	NULL
is	NULL
positively	NULL
associated	NULL
with	NULL
chronic	NULL
rejection	NULL
and	NULL
transplant	NULL
atherosclerosis	NULL
of	NULL
heart	NULL
and	NULL
renal	NULL
allografts	NULL
(	NULL
59-67	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
our	NULL
previous	NULL
data	NULL
and	NULL
the	NULL
current	NULL
studies	NULL
indicate	NULL
that	NULL
chronic	NULL
rejection	NULL
can	NULL
be	NULL
mediated	NULL
by	NULL
anti-HLA	NULL
Abs	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
endothelium	NULL
and	NULL
smooth	NULL
muscle	NULL
of	NULL
the	NULL
allograft-transducing	NULL
signals	NULL
that	NULL
ultimately	NULL
result	NULL
in	NULL
cell	NULL
proliferation	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
model	NULL
in	NULL
which	NULL
ligation	NULL
of	NULL
class	NULL
I	NULL
molecules	NULL
by	NULL
anti-HLA	NULL
Abs	NULL
stimulates	NULL
FGF	NULL
receptor	NULL
expression	NULL
and	NULL
increased	NULL
ligand	NULL
binding	NULL
.	NULL

Binding	NULL
of	NULL
FGF	NULL
triggers	NULL
a	NULL
series	NULL
of	NULL
downstream	NULL
events	NULL
resulting	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
cyclin	NULL
E-cdk2	NULL
.	NULL

Activated	NULL
cyclin	NULL
E-cdk2	NULL
relieves	NULL
the	NULL
inhibition	NULL
exerted	NULL
by	NULL
Rb	NULL
,	NULL
causing	NULL
the	NULL
EC	NULL
and	NULL
SMC	NULL
to	NULL
pass	NULL
the	NULL
G	NULL
,	NULL
checkpoint	NULL
and	NULL
pro-liferate	NULL
.	NULL

Since	NULL
signaling	NULL
through	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
can	NULL
induce	NULL
the	NULL
proliferation	NULL
of	NULL
vascular	NULL
EC	NULL
and	NULL
SMC	NULL
,	NULL
agents	NULL
that	NULL
block	NULL
this	NULL
process	NULL
may	NULL
be	NULL
useful	NULL
in	NULL
the	NULL
prevention	NULL
of	NULL
transplantation-associ-ated	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Elucidation	NULL
of	NULL
the	NULL
molecular	NULL
processes	NULL
involved	NULL
in	NULL
HLA	NULL
class	NULL
-mediated	NULL
signal	NULL
transduction	NULL
will	NULL
be	NULL
beneficial	NULL
in	NULL
identifying	NULL
agents	NULL
that	NULL
would	NULL
be	NULL
of	NULL
therapeutic	NULL
value	NULL
in	NULL
preventing	NULL
such	NULL
disease	NULL
processes	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Norbury	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
P.	NULL
Nurse	NULL
.	NULL

1992	NULL
.	NULL

Animal	NULL
cell	NULL
cycles	NULL
and	NULL
their	NULL
control	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

61:441	NULL
.	NULL

2	NULL
.	NULL

Murray	NULL
,	NULL
A.	NULL
W.	NULL
1992	NULL
.	NULL

Creative	NULL
blocks	NULL
:	NULL
cell	NULL
cycle	NULL
checkpoints	NULL
and	NULL
feedback	NULL
con-trols	NULL
.	NULL

Nature	NULL
359:599	NULL
.	NULL

3	NULL
.	NULL

Murray	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
T.	NULL
Hunt	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Cell	NULL
Cycle	NULL
:	NULL
An	NULL
Introduction	NULL
.	NULL

Oxford	NULL
University	NULL
Press	NULL
,	NULL
Oxford	NULL
.	NULL

4	NULL
.	NULL

Kamb	NULL
,	NULL
A	NULL
.	NULL

1995	NULL
.	NULL

Cell	NULL
cycle	NULL
regulators	NULL
and	NULL
cancer	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

11:136	NULL
.	NULL

5	NULL
.	NULL

Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
retinoblastoma	NULL
protein	NULL
and	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL

Cell	NULL
81:323	NULL
.	NULL

6	NULL
.	NULL

Paggi	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
A.	NULL
Baldi	NULL
,	NULL
F.	NULL
Bonetto	NULL
,	NULL
and	NULL
A.	NULL
Giordano	NULL
.	NULL

1996	NULL
.	NULL

Retinoblastoma	NULL
protein	NULL
family	NULL
in	NULL
cell	NULL
cycle	NULL
and	NULL
cancer	NULL
:	NULL
a	NULL
review	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

62:418	NULL
.	NULL

7	NULL
.	NULL

Pardee	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

1994	NULL
.	NULL

Multiple	NULL
molecular	NULL
levels	NULL
of	NULL
cell	NULL
cycle	NULL
regulation	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

54:375	NULL
.	NULL

8	NULL
.	NULL

Ewen	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
H.	NULL
K.	NULL
Sluss	NULL
,	NULL
C.	NULL
J.	NULL
Sher	NULL
,	NULL
H.	NULL
Matsushime	NULL
,	NULL
J.	NULL
Kato	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Livingston	NULL
.	NULL

1993	NULL
.	NULL

Functional	NULL
interactions	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
with	NULL
mammalian	NULL
D-type	NULL
cyclins	NULL
.	NULL

Cell	NULL
73:487	NULL
.	NULL

9	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
ins	NULL
and	NULL
outs	NULL
of	NULL
RB	NULL
:	NULL
coupling	NULL
gene	NULL
expression	NULL
to	NULL
the	NULL
cell	NULL
cycle	NULL
clock	NULL
.	NULL

Trends	NULL
Cell	NULL
.	NULL

Biol	NULL
.	NULL

4:15	NULL
.	NULL

10	NULL
.	NULL

Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
R.	NULL
Bernards	NULL
.	NULL

1996	NULL
.	NULL

Cell	NULL
cycle	NULL
regulation	NULL
by	NULL
the	NULL
retinoblastoma	NULL
family	NULL
of	NULL
growth	NULL
inhibitory	NULL
proteins	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1287:103	NULL
.	NULL

11	NULL
.	NULL

Lukas	NULL
,	NULL
J.	NULL
,	NULL
J.	NULL
Bartkova	NULL
,	NULL
and	NULL
J.	NULL
Bartek	NULL
.	NULL

1996	NULL
.	NULL

Convergence	NULL
of	NULL
mitogenic	NULL
signaling	NULL
cascades	NULL
from	NULL
diverse	NULL
classes	NULL
of	NULL
receptors	NULL
at	NULL
the	NULL
cyclin	NULL
D-cyclin-dependent-ki-nase-pRb-controlled	NULL
G	NULL
,	NULL
checkpoint	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:6917	NULL
.	NULL

12	NULL
.	NULL

Kato	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Matsushime	NULL
,	NULL
S.	NULL
W.	NULL
Hicbert	NULL
,	NULL
M.	NULL
E.	NULL
Ewen	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Sherr	NULL
.	NULL

1993	NULL
.	NULL

Direct	NULL
binding	NULL
of	NULL
cyclin	NULL
D	NULL
to	NULL
the	NULL
retinoblastoma	NULL
gene	NULL
product	NULL
(	NULL
pRb	NULL
)	NULL
and	NULL
pRb	NULL
phosphorylation	NULL
by	NULL
the	NULL
cyclin	NULL
D-dependent	NULL
kinase	NULL
CDK4	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:331	NULL
.	NULL

13	NULL
.	NULL

Kato	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
M.	NULL
Matsuoka	NULL
,	NULL
D.	NULL
K.	NULL
Strom	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Sherr	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
cyclin	NULL
D-dependent	NULL
kinase	NULL
4	NULL
(	NULL
cdk4	NULL
)	NULL
by	NULL
cdk4-activating	NULL
kinase	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:2713	NULL
.	NULL

14	NULL
.	NULL

Taya	NULL
,	NULL
Y	NULL
.	NULL

1997	NULL
.	NULL

RB	NULL
kinases	NULL
and	NULL
RB-binding	NULL
proteins	NULL
:	NULL
new	NULL
points	NULL
of	NULL
view	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

22:14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

5357	NULL
Lundberg	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Weinberg	NULL
.	NULL

1998	NULL
.	NULL

Functional	NULL
inactivation	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
requires	NULL
sequential	NULL
modification	NULL
by	NULL
at	NULL
least	NULL
two	NULL
distinct	NULL
cyclin-cdk	NULL
complexes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:753	NULL
.	NULL

Chellappan	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
S.	NULL
Hiebert	NULL
,	NULL
M.	NULL
Mudryj	NULL
,	NULL
J.	NULL
M.	NULL
Horowitz	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
E2F	NULL
transcription	NULL
factor	NULL
is	NULL
a	NULL
cellular	NULL
target	NULL
for	NULL
the	NULL
RB	NULL
protein	NULL
.	NULL

Cell	NULL
65:1053	NULL
.	NULL

Bagchi	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Weinmann	NULL
,	NULL
and	NULL
P.	NULL
Raychaudhuri	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
retinoblastoma	NULL
protein	NULL
copurifies	NULL
with	NULL
E2F-I	NULL
,	NULL
an	NULL
E1	NULL
A-regulated	NULL
inhibitor	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
E2F	NULL
.	NULL

Cell	NULL
65:1073	NULL
.	NULL

Chittenden	NULL
,	NULL
T.	NULL
,	NULL
D.	NULL
M.	NULL
Livingston	NULL
,	NULL
and	NULL
W.	NULL
G.	NULL
Kaelin	NULL
,	NULL
Jr.	NULL
1991	NULL
.	NULL

RB	NULL
associates	NULL
with	NULL
an	NULL
E2F-like	NULL
,	NULL
sequence-specific	NULL
DNA-binding	NULL
protein	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Symp	NULL
.	NULL

Quant	NULL
.	NULL

Biol	NULL
.	NULL

56:187	NULL
.	NULL

Chellappan	NULL
,	NULL
S.	NULL
P.	NULL
1994	NULL
.	NULL

The	NULL
E2F	NULL
transcription	NULL
factor	NULL
:	NULL
role	NULL
in	NULL
cell	NULL
cycle	NULL
regulation	NULL
and	NULL
differentiation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Differ	NULL
.	NULL

2:201	NULL
.	NULL

Dyson	NULL
,	NULL
N.	NULL
1998	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
E2F	NULL
by	NULL
pRB-family	NULL
proteins	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

12:2245	NULL
.	NULL

Nevins	NULL
,	NULL
J.	NULL
R.	NULL
1998	NULL
.	NULL

Toward	NULL
an	NULL
understanding	NULL
of	NULL
the	NULL
functional	NULL
complexity	NULL
of	NULL
the	NULL
E2F	NULL
and	NULL
retinoblastoma	NULL
families	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

9:585	NULL
.	NULL

Johnson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
and	NULL
R.	NULL
Schneider-Broussard	NULL
.	NULL

1998	NULL
.	NULL

Role	NULL
of	NULL
E2F	NULL
in	NULL
cell	NULL
cycle	NULL
control	NULL
and	NULL
cancer	NULL
.	NULL

Front	NULL
.	NULL

Biosci	NULL
.	NULL

3:4447	NULL
.	NULL

Shan	NULL
,	NULL
B.	NULL
,	NULL
X.	NULL
Zhu	NULL
,	NULL
P.	NULL
L.	NULL
Chen	NULL
,	NULL
T.	NULL
Durfee	NULL
,	NULL
Y.	NULL
Yang	NULL
,	NULL
D.	NULL
Sharp	NULL
,	NULL
and	NULL
W.	NULL
H.	NULL
Lee	NULL
.	NULL

1992	NULL
.	NULL

Regulation	NULL
of	NULL
E2F/cyclin	NULL
A-containing	NULL
complex	NULL
upon	NULL
retinoic	NULL
acid-induced	NULL
differentiation	NULL
of	NULL
teratocarcinoma	NULL
cells	NULL
.	NULL

Gene	NULL
Expression	NULL
2:259	NULL
.	NULL

Ikeda	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
L.	NULL
Jakoi	NULL
,	NULL
and	NULL
J.	NULL
R.	NULL
Nevins	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
unique	NULL
role	NULL
for	NULL
the	NULL
Rb	NULL
protein	NULL
in	NULL
controlling	NULL
E2F	NULL
accumulation	NULL
during	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:3215	NULL
.	NULL

Puri	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
L.	NULL
Cimino	NULL
,	NULL
M.	NULL
Fulco	NULL
,	NULL
C.	NULL
Zimmerman	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

La	NULL
Thangue	NULL
,	NULL
A.	NULL
Giordano	NULL
,	NULL
A.	NULL
Gracssmann	NULL
,	NULL
and	NULL
M.	NULL
Levrero	NULL
.	NULL

1998	NULL
.	NULL

Regulation	NULL
of	NULL
E2P4	NULL
mitogenic	NULL
activity	NULL
during	NULL
terminal	NULL
differentiation	NULL
by	NULL
its	NULL
heterodimerization	NULL
partners	NULL
for	NULL
nuclear	NULL
translocation	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

58:1325	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Ghosh	NULL
,	NULL
and	NULL
S.	NULL
Chellappan	NULL
.	NULL

1998	NULL
.	NULL

Raf-1	NULL
physically	NULL
interacts	NULL
with	NULL
Rb	NULL
and	NULL
regulates	NULL
its	NULL
function	NULL
:	NULL
a	NULL
link	NULL
between	NULL
mitogenic	NULL
signaling	NULL
and	NULL
cell	NULL
cycle	NULL
regulation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:7487	NULL
.	NULL

Dou	NULL
,	NULL
Q.	NULL
P.	NULL
,	NULL
B	NULL
.	NULL

An	NULL
,	NULL
K.	NULL
Antoku	NULL
,	NULL
and	NULL
D.	NULL
E.	NULL
Johnson	NULL
.	NULL

1997	NULL
.	NULL

Fas	NULL
stimulation	NULL
induces	NULL
RB	NULL
dephosphorylation	NULL
and	NULL
proteolysis	NULL
that	NULL
is	NULL
blocked	NULL
by	NULL
inhibitors	NULL
of	NULL
the	NULL
ICE	NULL
protease	NULL
family	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

64:586	NULL
.	NULL

Janicke	NULL
,	NULL
R.	NULL
U.	NULL
,	NULL
P.	NULL
A.	NULL
Walker	NULL
,	NULL
X.	NULL
Y.	NULL
Lin	NULL
,	NULL
and	NULL
A.	NULL
G.	NULL
Porter	NULL
.	NULL

1996	NULL
.	NULL

Specific	NULL
cleavage	NULL
of	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
by	NULL
an	NULL
ICE-like	NULL
protease	NULL
in	NULL
apoptosis	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:6969	NULL
.	NULL

Cobrinik	NULL
,	NULL
D.	NULL
1996	NULL
.	NULL

Regulatory	NULL
interactions	NULL
among	NULL
E2Fs	NULL
and	NULL
cell	NULL
cycle	NULL
proteins	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

208:32	NULL
.	NULL

Slansky	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farnham	NULL
.	NULL

1996	NULL
.	NULL

Introduction	NULL
to	NULL
the	NULL
E2F	NULL
family	NULL
:	NULL
protein	NULL
structure	NULL
and	NULL
gene	NULL
regulation	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

208:1	NULL
.	NULL

Bian	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
E.	NULL
Harris	NULL
,	NULL
A.	NULL
Mulder	NULL
,	NULL
and	NULL
E.	NULL
F.	NULL
Reed	NULL
.	NULL

1997	NULL
.	NULL

Anti-HLA	NULL
antibody	NULL
ligation	NULL
to	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
expressed	NULL
by	NULL
endothelial	NULL
cells	NULL
stimulates	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
inositol	NULL
phosphate	NULL
generation	NULL
,	NULL
and	NULL
proliferation	NULL
.	NULL

Hum	NULL
.	NULL

Immunol	NULL
.	NULL

53:90	NULL
.	NULL

Harris	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
H.	NULL
Bian	NULL
,	NULL
and	NULL
E.	NULL
F.	NULL
Reed	NULL
.	NULL

1997	NULL
.	NULL

Induction	NULL
of	NULL
high	NULL
affinity	NULL
fibroblast	NULL
growth	NULL
factor	NULL
receptor	NULL
expression	NULL
and	NULL
proliferation	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
by	NULL
anti-HLA	NULL
antibodies	NULL
:	NULL
a	NULL
possible	NULL
mechanism	NULL
for	NULL
transplant	NULL
atherosclerosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:5697	NULL
.	NULL

Bian	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
E.	NULL
Harris	NULL
,	NULL
and	NULL
E.	NULL
F.	NULL
Reed	NULL
.	NULL

1998	NULL
.	NULL

Ligation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
on	NULL
smooth	NULL
muscle	NULL
cells	NULL
with	NULL
anti-HLA	NULL
antibodies	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
fibroblast	NULL
growth	NULL
factor	NULL
receptor	NULL
expression	NULL
and	NULL
cell	NULL
proliferation	NULL
.	NULL

Inf	NULL
.	NULL

Immunol	NULL
.	NULL

10:1315	NULL
.	NULL

Haruhito	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
N.	NULL
L.	NULL
Tilney	NULL
.	NULL

1994	NULL
.	NULL

Chronic	NULL
graft	NULL
rejection	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

6:770	NULL
.	NULL

Paul	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
and	NULL
B.	NULL
Fellstrom	NULL
.	NULL

1992	NULL
.	NULL

Chronic	NULL
vascular	NULL
rejection	NULL
of	NULL
the	NULL
heart	NULL
and	NULL
kidney	NULL
:	NULL
have	NULL
rational	NULL
treatment	NULL
options	NULL
emerged	NULL
?	NULL

Transplantation	NULL
53:1169	NULL
.	NULL

Skov	NULL
,	NULL
S.	NULL
1998	NULL
.	NULL

Intracellular	NULL
signal	NULL
transduction	NULL
mediated	NULL
by	NULL
ligation	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

Tissue	NULL
Antigens	NULL
51:215	NULL
.	NULL

Bregenholt	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Ropke	NULL
,	NULL
S.	NULL
Skov	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Claesson	NULL
.	NULL

1996	NULL
.	NULL

Ligation	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
on	NULL
peripheral	NULL
blood	NULL
T-lymphocytes	NULL
induces	NULL
new	NULL
phenotypes	NULL
and	NULL
functions	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:993	NULL
.	NULL

Woodle	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
D.	NULL
M.	NULL
Smith	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
,	NULL
W.	NULL
M.	NULL
I.	NULL
Kirkman	NULL
,	NULL
D.	NULL
R.	NULL
Green	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Skowronrski	NULL
.	NULL

1997	NULL
.	NULL

Anti-human	NULL
class	NULL
I	NULL
MHC	NULL
antibodies	NULL
induce	NULL
apoptosis	NULL
by	NULL
a	NULL
pathway	NULL
that	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
Fas	NULL
antigen-mediated	NULL
pathway	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:2156	NULL
.	NULL

Genestier	NULL
,	NULL
L.	NULL
,	NULL
R.	NULL
Paillot	NULL
,	NULL
N.	NULL
Bonnefoy-Berard	NULL
,	NULL
G.	NULL
Meffre	NULL
,	NULL
M.	NULL
Flacher	NULL
,	NULL
D.	NULL
Fevre	NULL
,	NULL
Y.	NULL
J.	NULL
Liu	NULL
,	NULL
P.	NULL
Le	NULL
Bouteiller	NULL
,	NULL
H.	NULL
Waldman	NULL
,	NULL
V.	NULL
H.	NULL
Englehard	NULL
,	NULL
J.	NULL
Banchereau	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Revillard	NULL
.	NULL

1997	NULL
.	NULL

Pas-independent	NULL
apoptosis	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
antibodies	NULL
to	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
a	NULL
domain	NULL
.	NULL

Blood	NULL
90:3629	NULL
.	NULL

Roosnek	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Tunnacliffe	NULL
,	NULL
and	NULL
A.	NULL
Lanzavecchia	NULL
.	NULL

1990	NULL
.	NULL

T-cell	NULL
activation	NULL
by	NULL
a	NULL
bispecific	NULL
anti-CD3/anti-major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
antibody	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20:1393	NULL
.	NULL

Geppert	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
L.	NULL
S.	NULL
Davis	NULL
,	NULL
H.	NULL
Gur	NULL
,	NULL
M.	NULL
C.	NULL
Wacholtz	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1990	NULL
.	NULL

Accessory	NULL
signals	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

117:5	NULL
.	NULL

Wacholtz	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
S.	NULL
S.	NULL
Patel	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1989	NULL
.	NULL

Patterns	NULL
of	NULL
costimulation	NULL
of	NULL
T-cell	NULL
clones	NULL
by	NULL
cross-linking	NULL
CD3	NULL
,	NULL
CD4/CD8	NULL
,	NULL
and	NULL
class	NULL
I	NULL
MHC	NULL
molecules	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:4201	NULL
.	NULL

Geppert	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
by	NULL
immobilized	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
CD3	NULL
:	NULL
regulatory	NULL
influences	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
additional	NULL
T	NULL
cell	NULL
surface	NULL
determinants	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

81:1497	NULL
.	NULL

Geppert	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
M.	NULL
C.	NULL
Wacholtz	NULL
,	NULL
L.	NULL
S.	NULL
Davis	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
T4	NULL
cells	NULL
by	NULL
cross-linking	NULL
class	NULL
I	NULL
MHC	NULL
molecules	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

140	NULL
;	NULL
2155	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
5358	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

Hansen	NULL
,	NULL
N.	NULL
Q.	NULL
,	NULL
T.	NULL
Tscherning	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Claesson	NULL
.	NULL

1990	NULL
.	NULL

T-cell	NULL
activation	NULL
.	NULL

IV	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
functional	NULL
linkage	NULL
between	NULL
MHC	NULL
class	NULL
I	NULL
,	NULL
IL2	NULL
and	NULL
IL4	NULL
receptor	NULL
molecules	NULL
.	NULL

Cytokine	NULL
3:35	NULL
.	NULL

Dissing	NULL
,	NULL
S.	NULL
,	NULL
C.	NULL
Geisler	NULL
,	NULL
B.	NULL
Rubin	NULL
,	NULL
T.	NULL
Plesner	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Claesson	NULL
.	NULL

1990	NULL
.	NULL

T-cell	NULL
activation	NULL
.	NULL

II	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
T	NULL
lymphoma	NULL
cells	NULL
by	NULL
cross-linking	NULL
of	NULL
their	NULL
MHC	NULL
class	NULL
I	NULL
antigens	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

126:196	NULL
.	NULL

Geppert	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
M.	NULL
C.	NULL
Walcholtz	NULL
,	NULL
S.	NULL
S.	NULL
Patel	NULL
,	NULL
E.	NULL
Lightfoot	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
T-cell	NULL
clones	NULL
and	NULL
Jurkat	NULL
cells	NULL
by	NULL
cross-linking	NULL
class	NULL
I	NULL
MHC	NULL
molecules	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:3763	NULL
.	NULL

Crawley	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
L.	NULL
Rawlinson	NULL
,	NULL
F.	NULL
V.	NULL
Lali	NULL
,	NULL
T.	NULL
H.	NULL
Page	NULL
,	NULL
J.	NULL
Saklatvala	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Foxwell	NULL
.	NULL

1997	NULL
.	NULL

T	NULL
cell	NULL
proliferation	NULL
in	NULL
response	NULL
to	NULL
interleukins	NULL
2	NULL
and	NULL
7	NULL
requires	NULL
p38	NULL
MAP	NULL
kinase	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:15023	NULL
.	NULL

Lee	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
P.	NULL
R.	NULL
Young	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
CSB/p38/RK	NULL
stress	NULL
response	NULL
kinase	NULL
in	NULL
LPS	NULL
and	NULL
cytokine	NULL
signaling	NULL
mechanisms	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

59:152	NULL
.	NULL

Kyriakis	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
J.	NULL
Avruch	NULL
.	NULL

1996	NULL
.	NULL

Protein	NULL
kinase	NULL
cascades	NULL
activated	NULL
by	NULL
stress	NULL
and	NULL
inflammatory	NULL
cytokines	NULL
.	NULL

Bioessays	NULL
18:567	NULL
.	NULL

Morooka	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
E.	NULL
Nishida	NULL
.	NULL

1998	NULL
.	NULL

Requirement	NULL
of	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
for	NULL
neuronal	NULL
differentiation	NULL
in	NULL
PC12	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:24285	NULL
.	NULL

Nagata	NULL
,	NULL
Y.	NULL
,	NULL
N.	NULL
Takahashi	NULL
,	NULL
R.	NULL
J.	NULL
Davis	NULL
,	NULL
and	NULL
K.	NULL
Todokoro	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
p38	NULL
MAP	NULL
kinase	NULL
and	NULL
JNK	NULL
but	NULL
not	NULL
ERK	NULL
is	NULL
required	NULL
for	NULL
erythropoictin-induced	NULL
ery-throid	NULL
differentiation	NULL
.	NULL

Blood	NULL
92:1859	NULL
.	NULL

Lukas	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Herzinger	NULL
,	NULL
K.	NULL
Hansen	NULL
,	NULL
M.	NULL
C.	NULL
Moroni	NULL
,	NULL
D.	NULL
Resnitzky	NULL
,	NULL
K.	NULL
Helin	NULL
,	NULL
S.	NULL
I.	NULL
Reed	NULL
,	NULL
and	NULL
J.	NULL
Bartek	NULL
.	NULL

1997	NULL
.	NULL

Cyclin	NULL
E-induced	NULL
S	NULL
phase	NULL
without	NULL
activation	NULL
of	NULL
the	NULL
pRb/E2F	NULL
pathway	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:1479	NULL
.	NULL

Duronio	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
P.	NULL
C.	NULL
Bonnette	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
O'Farrell	NULL
.	NULL

1998	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
Drosophila	NULL
dDP	NULL
,	NULL
dE2F	NULL
,	NULL
and	NULL
cyclin	NULL
E	NULL
genes	NULL
reveal	NULL
distinct	NULL
roles	NULL
for	NULL
the	NULL
E2F-DP	NULL
transcription	NULL
factor	NULL
and	NULL
cyclin	NULL
E	NULL
during	NULL
the	NULL
G	NULL
,	NULL
-S	NULL
transition	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:141	NULL
.	NULL

Zhao	NULL
,	NULL
X.	NULL
M.	NULL
,	NULL
T.	NULL
K.	NULL
Yeoh	NULL
,	NULL
M.	NULL
Hiebert	NULL
,	NULL
W.	NULL
H.	NULL
Frist	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
Miller	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
acidic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
(	NULL
heparin-binding	NULL
growth	NULL
factor-1	NULL
)	NULL
and	NULL
cytokine	NULL
genes	NULL
in	NULL
human	NULL
cardiac	NULL
allografts	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

Transplantation	NULL
56:1177	NULL
.	NULL

Zhao	NULL
,	NULL
X.	NULL
M.	NULL
,	NULL
T.	NULL
K.	NULL
Yeoh	NULL
,	NULL
W.	NULL
H.	NULL
Frist	NULL
,	NULL
D.	NULL
L.	NULL
Porterfield	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
Miller	NULL
.	NULL

1994	NULL
.	NULL

Induction	NULL
of	NULL
acidic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
and	NULL
full-length	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
expression	NULL
in	NULL
human	NULL
cardiac	NULL
allografts	NULL
:	NULL
analysis	NULL
by	NULL
PCR	NULL
,	NULL
in	NULL
situ	NULL
hybridization	NULL
,	NULL
and	NULL
immunchistochemistry	NULL
.	NULL

Circulation	NULL
90:677	NULL
.	NULL

Zhao	NULL
,	NULL
X.	NULL
M.	NULL
,	NULL
W.	NULL
H.	NULL
Frist	NULL
,	NULL
T.	NULL
K.	NULL
Yeoh	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
Miller	NULL
.	NULL

1994	NULL
.	NULL

Modification	NULL
of	NULL
alternative	NULL
messenger	NULL
RNA	NULL
splicing	NULL
of	NULL
fibroblast	NULL
growth	NULL
factor	NULL
receptors	NULL
in	NULL
human	NULL
cardiac	NULL
allografts	NULL
during	NULL
rejection	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:992	NULL
.	NULL

Kerby	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
D.	NULL
J.	NULL
Verran	NULL
,	NULL
K.	NULL
L.	NULL
Luo	NULL
,	NULL
Q.	NULL
Ding	NULL
,	NULL
Y.	NULL
Tagouri	NULL
,	NULL
G.	NULL
A.	NULL
Herrera	NULL
,	NULL
A.	NULL
G.	NULL
Diethelm	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Thompson	NULL
.	NULL

1996	NULL
.	NULL

Immunolocalization	NULL
of	NULL
FGF-1	NULL
and	NULL
59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

HLA	NULL
CLASS	NULL
I-MEDIATED	NULL
CELL	NULL
PROLIFERATION	NULL
receptors	NULL
in	NULL
human	NULL
renal	NULL
allograft	NULL
vasculopathy	NULL
associated	NULL
with	NULL
chronic	NULL
rejection	NULL
.	NULL

Transplantation	NULL
62:467	NULL
.	NULL

Fenoglio	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Ho	NULL
,	NULL
E.	NULL
Reed	NULL
,	NULL
E.	NULL
Rose	NULL
,	NULL
C.	NULL
Smith	NULL
,	NULL
K.	NULL
Reemstma	NULL
,	NULL
C.	NULL
Marboe	NULL
,	NULL
and	NULL
N.	NULL
Suciu-Foca	NULL
.	NULL

1989	NULL
.	NULL

Anti-HLA	NULL
antibodies	NULL
and	NULL
heart	NULL
allograft	NULL
survival	NULL
.	NULL

Transplant	NULL
.	NULL

Proc	NULL
.	NULL

21:807	NULL
.	NULL

Suciu-Foca	NULL
,	NULL
N.	NULL
,	NULL
E.	NULL
Reed	NULL
,	NULL
V.	NULL
D.	NULL
D'Agati	NULL
,	NULL
E.	NULL
Ho	NULL
,	NULL
D.	NULL
J.	NULL
Cohen	NULL
,	NULL
A.	NULL
I.	NULL
Benvenisty	NULL
,	NULL
R.	NULL
McCabe	NULL
,	NULL
J.	NULL
M.	NULL
Brensilver	NULL
,	NULL
D.	NULL
W.	NULL
King	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Hardy	NULL
.	NULL

1991	NULL
.	NULL

Soluble	NULL
HLA	NULL
antigens	NULL
,	NULL
anti-HLA	NULL
antibodies	NULL
,	NULL
and	NULL
antiidiotypic	NULL
antibodies	NULL
in	NULL
the	NULL
circulation	NULL
of	NULL
renal	NULL
transplant	NULL
recipients	NULL
.	NULL

Transplantation	NULL
51:593	NULL
.	NULL

Suciu-Foca	NULL
,	NULL
N.	NULL
,	NULL
E.	NULL
Reed	NULL
,	NULL
C.	NULL
Marboe	NULL
,	NULL
P.	NULL
Harris	NULL
,	NULL
P.	NULL
X.	NULL
Yu	NULL
,	NULL
Y.	NULL
K.	NULL
Sun	NULL
,	NULL
E.	NULL
Ho	NULL
,	NULL
E.	NULL
Rose	NULL
,	NULL
K.	NULL
Reemtsma	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
King	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
anti-HLA	NULL
antibodies	NULL
in	NULL
heart	NULL
transplantation	NULL
.	NULL

Transplantation	NULL
51:716	NULL
.	NULL

Ende	NULL
,	NULL
N.	NULL
,	NULL
E.	NULL
V.	NULL
Orsi	NULL
,	NULL
N.	NULL
Z.	NULL
Baturay	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Britten	NULL
.	NULL

1979	NULL
.	NULL

Properties	NULL
of	NULL
a	NULL
cytotoxic	NULL
|	NULL
kidney	NULL
antibody	NULL
associated	NULL
with	NULL
human	NULL
renal	NULL
transplantation	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Pathol	NULL
.	NULL

71:543	NULL
.	NULL

Duijvestijn	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
van	NULL
Breda	NULL
Vriesman	NULL
.	NULL

1991	NULL
.	NULL

Chronic	NULL
renal	NULL
allograft	NULL
rejection	NULL
:	NULL
selective	NULL
involvement	NULL
of	NULL
the	NULL
glomerular	NULL
endothelium	NULL
in	NULL
humoral	NULL
immune	NULL
reactivity	NULL
and	NULL
intravascular	NULL
coagulation	NULL
.	NULL

Transplantation	NULL
52:195	NULL
.	NULL

Cherry	NULL
,	NULL
R.	NULL
,	NULL
H.	NULL
Nielsen	NULL
,	NULL
E.	NULL
Reed	NULL
,	NULL
K.	NULL
Reemtsma	NULL
,	NULL
N.	NULL
Suciu-Foca	NULL
,	NULL
and	NULL
C.	NULL
C.	NULL
Marboe	NULL
.	NULL

1992	NULL
.	NULL

Vascular	NULL
(	NULL
humoral	NULL
)	NULL
rejection	NULL
in	NULL
human	NULL
cardiac	NULL
allograft	NULL
biopsies	NULL
:	NULL
relation	NULL
to	NULL
circulating	NULL
anti-HLA	NULL
antibodies	NULL
.	NULL

J	NULL
.	NULL

Heart	NULL
Lung	NULL
Transplant	NULL
.	NULL

11:24	NULL
.	NULL

Davenport	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
E.	NULL
Younie	NULL
,	NULL
J.	NULL
E.	NULL
Parsons	NULL
,	NULL
and	NULL
P.	NULL
T.	NULL
Klouda	NULL
.	NULL

1994	NULL
.	NULL

Development	NULL
of	NULL
cytotoxic	NULL
antibodies	NULL
following	NULL
renal	NULL
allograft	NULL
transplantation	NULL
is	NULL
associated	NULL
with	NULL
reduced	NULL
graft	NULL
survival	NULL
due	NULL
to	NULL
chronic	NULL
vascular	NULL
rejection	NULL
.	NULL

Nephrol	NULL
.	NULL

Dial	NULL
.	NULL

Transplant	NULL
.	NULL

9:1315	NULL
.	NULL

Costa	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
M.	NULL
P.	NULL
Scolari	NULL
,	NULL
S.	NULL
Iannelli	NULL
,	NULL
A.	NULL
Buscaroli	NULL
,	NULL
G.	NULL
L.	NULL
D'Arcangelo	NULL
,	NULL
B.	NULL
Brando	NULL
,	NULL
F.	NULL
Indiveri	NULL
,	NULL
M.	NULL
Savi	NULL
,	NULL
L.	NULL
C.	NULL
Borgnino	NULL
,	NULL
L.	NULL
B.	NULL
DeSanctis	NULL
,	NULL
S.	NULL
Stefoni	NULL
,	NULL
and	NULL
V.	NULL
Bonomini	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
posttransplant	NULL
HLA-specific	NULL
IgG	NULL
antibodies	NULL
detected	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
correlates	NULL
with	NULL
specific	NULL
rejection	NULL
pathologies	NULL
.	NULL

Transplantation	NULL
63:167	NULL
.	NULL

Reed	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
B.	NULL
Hong	NULL
,	NULL
E.	NULL
Ho	NULL
,	NULL
P.	NULL
E.	NULL
Harris	NULL
,	NULL
J.	NULL
Weinberger	NULL
,	NULL
and	NULL
N.	NULL
Suciu-Foca	NULL
.	NULL

1996	NULL
.	NULL

Monitoring	NULL
of	NULL
soluble	NULL
HLA	NULL
alloantigens	NULL
and	NULL
anti-HLA	NULL
antibodies	NULL
identifies	NULL
heart	NULL
allograft	NULL
recipients	NULL
at	NULL
risk	NULL
of	NULL
transplant-associated	NULL
coronary	NULL
artery	NULL
disease	NULL
.	NULL

Transplantation	NULL
61:566	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
S.	NULL
P.	NULL
Chellappan	NULL
.	NULL

1996	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Differ	NULL
.	NULL

4:297	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
,	NULL
N.	NULL
Nath	NULL
,	NULL
A.	NULL
Minden	NULL
,	NULL
and	NULL
S.	NULL
Chellappan	NULL
.	NULL

1999	NULL
.	NULL

Regulation	NULL
of	NULL
Rb	NULL
and	NULL
E2F	NULL
by	NULL
signal	NULL
transduction	NULL
cascades	NULL
:	NULL
divergent	NULL
effects	NULL
of	NULL
JNK1	NULL
and	NULL
p38	NULL
kinases	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

18:1559	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
/310°	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

